



ANNUAL REPORT

2018-19



Indo-Bangla Pharmaceuticals Ltd.

Good Health Good Life

www.indo-banglapharma.com

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ



VISION

**"BE ON THE FOREFRONT OF CHANGING
HEALTHCARE ENVIRONMENT TURNING
INNOVATIVE SCIENCE TOWARDS
ESTEEMED NEW TREATMENT REFERENCES"**



**“TO PROVIDE INNOVATIVE AND
QUALITY MEDICINES TO IMPROVE THE
HUMAN BEINGS IN ARENA OF HEALTH
IN NEED FOR BEST TREATMENTS”**

MISSION

BANGLADESH ASSOCIATION OF PUBLICLY LISTED COMPANIES

Ref. No: CM-2019/258

Date of issue : October 24, 2019



Certificate of Membership

This is to certify that

INDO-BANGLA PHARMACEUTICALS LIMITED

is an Ordinary Member of Bangladesh Association of Publicly Listed Companies and is entitled to all the rights and privileges appertaining thereto.

This certificate remains current until 31st December 2019.




Secretary-General



বাংলাদেশ ঔষধ শিল্প সমিতি
BANGLADESH ASSOCIATION OF PHARMACEUTICAL INDUSTRIES
Navana Osman@Link (Level-4), 214/D Bir Uttam Mir Shawkat Avenue
Tejgaon-Gulshan Link Road, Dhaka-1208. Fax: 88-02-8823651
Phone: 88-02-58816767, 9889731, 8824163 E-mail: bdass@bol-online.com

CERTIFICATE OF MEMBERSHIP

CERTIFICATE NO.

1116

MEMBERSHIP NO.

BASS/MD-2018/68

INDO-BANGLA PHARMACEUTICALS LTD.

College Road, Barisal

This is to certify that M/s
.....
is a member of *Bangladesh Ashad Shilpa Samity*.
This Association is duly licensed by the Ministry of Commerce, Government of the People's Republic of Bangladesh under reference License No. 3 of 1973 and incorporated with the Registrar of Joint Stock Companies, Bangladesh bearing Certificate No. 3898-B of 1972-1973.
147

This Association is also affiliated with the Federation of Bangladesh Chambers of Commerce and Industry (FBCCI) Dhaka and International Federation of Pharmaceutical Manufacturers' Associations (IFPMA) Geneva.

This Certificate is valid upto 31st December **2018**

Zinul Haq

Secretary
Secretary/Secretary General
(Bangladesh Ashad Shilpa Samity)



Nazmul Hassan

Nazmul Hassan, MP
President
Bangladesh Ashad Shilpa Samity



CONTENTS

Letter of Transmittal	07
Notice of the Annual General Meeting	08
Shareholders View of the 4th AGM	09-10
Company Profile	11-12
The Board of Directors	13
Management Apparatus	14
Chairman's Statement	15
Managing Director's Statement	16
Corporate Governance	18-21
We Offer	23
Manufacturing Capabilities	23
Our People	24
Corporate Social Responsibilities	25
Product Portfolio	26-30
Corporate Operational Results	31
Directors' Report to the Shareholders	32-42
Statement of Directors' on Financial Reports	43
Directors' Re-Appointment	44-45
Shareholding Pattern	46
Report on the Activities of the Audit Committee	47
Report on the Activities of the Nomination and Remuneration Committee	48-49
Managing Director & CFO's Declaration	50
Certificate on Compliance of Corporate Governance Guidelines	51
Corporate Governance Compliance Report	52-63
Independent Auditors' Report	64-66
Statement of Financial Position	67
Statement of Profit or Loss and Other Comprehensive Income	68
Statement of Changes in Equity	69
Statement of Cash Flows	70
Notes to the Financial Statements	71-91
Proxy Form & Attendance Slip	92

LETTER OF TRANSMITTAL

All Shareholders
Bangladesh Securities and Exchange Commission
Dhaka Stock Exchange Limited
Chittagong Stock Exchange Limited
Registrar of Joint Stock Companies & Firm

ANNUAL REPORT FOR THE YEAR ENDED JUNE 30, 2019

Dear Sir/Madam (s)

We are pleased to enclose a copy of the Annual Report containing Directors' Report, Auditors' Report along with Audited Financial Statements including Statement of Financial Position as at June 30, 2019, Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows for the Year ended June 30, 2019 along with notes thereon.

We in our endeavor have tried our best to make fair disclosures on our financial & non-financial matter as part of our integrated reporting for your kind perusal and record.

Thanking you.

Very truly yours:



Mohi Uddin QCS
Company Secretary

Dated: 20th November, 2019.



Indo-Bangla Pharmaceuticals Ltd.

Bashundhara R/A, Baridhara, Dhaka-1229

NOTICE OF THE 5TH ANNUAL GENERAL MEETING (AGM)

Notice is hereby given that the 5th ANNUAL GENERAL MEETING of the Members of Indo-Bangla Pharmaceuticals Ltd. will be held on **Thursday the 12th December 2019 at 10:00 a.m.** at **"Nishorgo Entertainment Zone, Nabogram, Barisal-8200** to transact the following business.

- Agenda-1:** To receive, consider and adopt the Audited Financial Statements for the year ended 30th June, 2019 together with the Report of the Directors' and Auditors' thereon.
- Agenda-2:** To declare dividend for the year ended 30th June, 2019.
- Agenda-3:** To elect Directors in terms of the relevant provisions of Articles of Association.
- Agenda-4:** To appoint Statutory Auditors for the year 2019-2020 and to fix their remuneration.
- Agenda-5:** To appoint Compliance Auditors for the year 2019-2020 and to fix their remuneration.
- Agenda-6:** To re-appoint the Managing Director.
- Agenda-7:** To re-appoint the Independent Director.
- Agenda-8:** To transact any other business with the permission of the Chair.

November 27, 2019

Mohi Uddin QCS
Company Secretary.

Note:

01. The Shareholders whose names will appear in the Share Register of the Company or Depository Register of CDBL as on the Record Date i.e. November 21, 2019 will be eligible to attend the 5TH Annual General Meeting (AGM) and qualify for the dividend.
02. A member entitled to attend and vote at the Annual General Meeting may appoint a Proxy to attend and vote in his/her behalf. Proxy form must be affixed with requisite revenue stamp and must be submitted at the corporate office of the Company, not more than 48 hours before the time fixed for the meeting.
03. Admission to the meeting will be strictly depending on production of the attendance slip sent with the notice as well as verification of signature of Members/ (S) and/or Proxy holders/(s).
04. Shareholders are requested to update their BO account with ETIN in their respective Brokerage House to avoid deduction of 15% tax instead of 10% for individuals as per Section 54 of the amended Income Tax Ordinance, 1984.

N.B: In compliance with Bangladesh Securities and Exchange Commission's Circular No. BSEC/CMRRCD/2009193/154 dated October 24, 2013, no gift/gift coupon/food box/benefit in cash or in kind shall be distributed/paid to the Shareholders for attending the 05th Annual General Meeting.

SHAREHOLDERS VIEW OF 4TH AGM



SHAREHOLDERS VIEW OF 4TH AGM





ABOUT INDO-BANGLA PHARMACEUTICALS LTD.


Indo-Bangla Pharmaceuticals Limited, the prevalent pharmaceuticals company in the Country, is a reliable name in the pharmaceuticals sector of Bangladesh. Like most local concerns, it made its inauguration in a humble way in 1954, founded by Ram Lal Vattracharjo in the heart of Barisal in the name of Indo-Pak Pharmaceutical Works (IPW). At that time, Indo-Pak Pharmaceutical Works started its business aiming to fulfill the basic healthcare demand of the people of Bangladesh. After independence, the government took control of the company and it was registered in Bangladesh under the privatization act in the name of Indo-Bangla Pharmaceutical Works. Later in 1982, the government sold the company through auction to a reputed businessman of Barisal, late Alhaj Shamsuddin Talukder and late Alhaj Azizul Haque. They started commercial operation with producing high quality medicine at a reasonable price with a goal to reach the healthcare services to the door step of the common people of Bangladesh as well as all over the world.

On June 18, 2014, Indo-Bangla Pharmaceuticals Works converted into a Private Limited Company under the Companies Act 1994, vide registration no. C116665/14. Subsequently on 21 October 2014, it converted into a Public Limited Company and became a Publicly Listed Company listed with Dhaka and Chittagong Stock Exchange Ltd., in 2018.

Since established, Indo-Bangla committed to provide high quality medicines, business success with ensuring ethical standards and responsible to valuable customer/patient. Our tradition and our values are the foundation of our mission to ensure health, heartiness and happiness for mankind.

We are an ISO 9001:2008 certified company and committed to improving the quality of human life by enabling people to do more, feel better and live longer. We also believe and adhere to values like Quality, Knowledge and Responsibility in all aspects of its operation and earned respect and recognition of its valued customers as well as to emphasize on the quality of product, process and services leading to the growth of the company imbued with good governance practices.

CORPORATE INFORMATION

Registered name of the company	Indo-Bangla Pharmaceuticals Ltd.
Company Logo	
Legal Form	A Private Limited Company incorporated in Bangladesh on June 18, 2014 under The Companies Act, 1994 (Reg. no. C-116665/14) and converted into Public Limited Company on October 21, 2014. The company was listed with Dhaka and Chittagong Stock Exchange on October 2018.
Converted Public Limited Company	21-Oct-14
Commencement of Commercial Operation	18-Jun-2014
Registered Office	729, College Road, Barisal Sadar, Barisal-8200.
Corporate Office	Plot No. # 183 (7th Floor), Block # B, Ahmed Akbar Sobhan Road, Bashundhara R/A, Baridhara, Dhaka-1229.
Factory Address	729, College Road, Barisal Sadar, Barisal-8200.
Tax Identification Number	681332543219
VAT Registration Number	15101029766
Website Address	www.indo-banglapharma.com
E-mail Address	info@indo-banglapharma.com,
Import Identification Number	260306120000319
Export Identification Number	260306210000519
Authorized Capital	BDT 1500 million
Paid-up Capital	BDT 1023 million
Nature of Business	The Company is engaged in manufacturing and selling of all kinds of medicine (excluding Antibiotic), medical preparations drugs & chemicals (Human Health). The Company applied for permission for production and selling of veterinary medicine also.
Statutory Auditor	Mahfel Huq & Co., Chartered Accountants
Compliance Auditor	Shafiq Basak of Co., Chartered Accountants
Membership	Bangladesh Association of Publicly Listed Companies (BAPLC) Bangladesh Association of Pharmaceutical Industries.(BAPI)



BOARD OF DIRECTORS



Mrs. Aziza Yeasmin
Chairman

Mrs. Aziza Yeasmin, is a Director of the Company since 2014 and has been appointed as Chairman. He is daughter of late Azizul huq, Founder of Indo-Bangla Pharmaceuticals Works, converted into a Private Limited Company under the companies Act 1994, on 21 October 2014, after than converted into a Public Limited Company and become Publicly Listed Company in 2018. She obtained Bachelor's degree from National University and has a rich experience of more than 12 years in the pharmaceuticals sector.

Mrs. Hafiza Yeasmin	Director
Md. Amin-Ur-Rashid	Director
Mrs. Sayeda Huq	Director
Mrs. Fatima Parvin	Director
Mst. Shahanaz Akter	Director
Md. Mizanur Rahman	Director
Md. Golam Rabbani	Director Representative of ICB.
S.M. Harun Or Rashid	Independent Director
Md. Monirujjaman	Independent Director
Md. Firoz Khan	Independent Director



Mr. A F M Anowarul Huq.
Managing Director

Mr. AFM Anowarul Huq, is a Director of the Company since 2014 and has been appointed as Managing Director in 2014. He is the son of late Azizul Huq, founder of Indo-Bangla Pharmaceuticals Works. He obtained Master's Degree in Applied Chemistry, LLB degree from the National University and obtained certificate of completion on GMP Training in Various Countries by WHO. Having a prosperous experience of more than 21 years in Pharmaceuticals, Shipping, Apparels as well as others family Business.

Mr. Huq also a Sponsor Director in others private limited company namely HBS Apparels Limited., Talukder Dairy Firm Limited., IBP Agrovet Ltd., Sabila Sea Foods Ltd., BD Pharma Ltd.,

Mr. Huq was a Former President of Rotary club of Barisal Mid Town; Apex club of Barisal; Chairman of Employers Committee UCEP, Barisal; Director of the Barisal Chamber of Commerce & Industry; Director of FBCCI;

At present he is the member of Ghatail Golf Club (GGC), Bangladesh Association of Publicly Listed Companies (BAPLC), Bangladesh Association of Pharmaceuticals Industries (BAPI), Bangladesh Aushad Shilpa Samity; lifetime member of Barisal Club Ltd, Barisal; Diabetic Hospital, Barisal; Red Crescent, Barisal; Heart Foundation, Barisal; Anjuman-E Hemayat-E Islam, Barisal.

MANAGEMENT APPARATUS



Board of Directors

- | | |
|------------------------|--------------------------------|
| • Aziza Yeasmin | Chairman |
| • A F M Anowarul Huq | Managing Director |
| • HafizaYeasmin | Director |
| • Md. Amin-Ur-Rashid | Director |
| • Sayeda Huq | Director |
| • Fatima Parvin | Director |
| • Mst. Shahanaz Akter | Director |
| • Md. Mizanur Rahman | Director |
| • Md. Golam Rabbani | Director Representative of ICB |
| • S.M. Harun Or Rashid | Independent Director |
| • Md. Monirujjaman | Independent Director |
| • Md. Firoz Khan | Independent Director |

Audit Committee

- | | |
|------------------------|----------|
| • S.M. Harun Or Rashid | Chairman |
| • Md. Amin-Ur-Rashid | member |
| • Fatima Parvin | Member |

Nomination and Remuneration Committee

- | | |
|----------------------|----------|
| • Md. Monirujjaman | Chairman |
| • Sayeda Huq | Member |
| • Md. Mizanur Rahman | Member |

Company Secretary

- | | |
|-------------------|--------------------|
| • Mohi Uddin, QCS | Company Secretary. |
|-------------------|--------------------|

Management Team

- | | |
|-----------------------|---------------------------------------|
| • A F M AnowarulH | Managing Director |
| • Md. Faruque Hossain | Chief Financial Officer |
| • Md. Abu Taleb | Head of Internal Audit and Compliance |
| • Shah E Azam | Plant Manager |
| • Mrs. Dilruba Begum | Head of QA |
| • Mr. Mizanur Rahman | Head of Admin |

CHAIRMAN'S STATEMENT



Mrs. Aziza Yeasmin



Bismillahir Rahamanir Rahim

The Beloved Shareholders,

Assalamu Alaikum Wa Rahmatullah.

We are delighted to welcome you at the 5th Annual General Meeting of the Indo-Bangla Pharmaceuticals Ltd. In this auspicious event I am pleased to place before you the "Annual Report 2018-2019" along with the Audited Financial statements, the Auditors' Report and the Directors' Report thereon for the year ended 30th June, 2019.

We are happy to inform you that in this year 2018-2019, Indo-Bangla Pharmaceuticals Ltd. passed a successful year maintained its sustainable achievement in terms of Earning Per Share (EPS), Net Operating Cash flow and profit earning as well. The Gross Profit, Operating Profit and Net Profit (BT) increased during FY 2018-19 at 13.88%, 16.39% and 19.30% respectively over the previous year. However, the Cost of Goods Sold increased at 11.16% over previous year which helped increase Gross Profit and Operating Profit. The Net Profit (AT), however, increased by 57.60% and Earning Per Share increased by 31.67% over the previous year reflect our efficiency in achievement of growth landmark, driven by implement of different business strategy like, to provide better medicine and healthcare services by enhancing the product portfolio with innovations as well as by efficient marketing policy and using the latest technologies in production plant.

The business policy and our priority is to drive long term value for investors through renewed focus on innovation and improving performance of Company to ensure maximum shareholders return and believe that the future development of Indo-Bangla Pharmaceuticals Ltd. including overall function of the company alongside the management of the Company would be ensured by your vigorous cooperation and suggestion.

Bangladesh is inching ahead in doing business climate index and other socio-economic indices and had made remarkable progress in the growth rate of GDP and has already entered the socio-economic classification of Lower Middle Income Group targeting to reach higher Middle Income Group by 2021 and Higher Income Group by 2041. As a result GDP growth continues, the per capita income would rise leading to higher health care expenditures by families as well as the government. This is expected to augment the demand for pharmaceuticals at a higher rate than the existing level.

Based on the success of 2018-2019, on behalf of the Board of Directors, I would like to express my sincere acknowledgement to the contribution made by the management team and employees of all levels for their tireless efforts. I also would like to express my heartfelt gratitude to our valued Shareholders, Customers, healthcare professionals, Suppliers, Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange (DSE), Chittagong Stock Exchange (CSE), Central Depository Bangladesh Limited (CDBL), Registrar of Joint Stock Companies and Firms (RJSC), Government agencies and all concerned for their continued support.

Thanking you all with best wishes and kindest regards.

Sd/-

Aziza Yeasmin
Chairman

STATEMENT FROM MANAGING DIRECTOR.



Indo-Bangla Pharmaceutical Ltd. has passed a successful year.

Bismillahir Rahamanir Rahim

The Beloved Shareholders,

Assalamu Alaikum Wa Rahmatullah.

This is a great moment for me to be here with you at the 5th Annual General Meeting of Indo-Bangla Pharmaceuticals Ltd. On behalf of the Board of Directors and myself, I express my earnest appreciations and profound gratitude to you for your enormous support and coordination. It is also my privilege to present you Company's Annual Report for the Year ended June 30, 2019 showing the financial position, achievement and notable performance of the Company.

Pharmaceutical sector is one the fastest growing industry and creating the enormous scope for better economic development of the country because of two effective policies have accelerated the growth of the sector. One was the Drug Control Ordinance 1982, which banned foreign companies from selling imported pharmaceutical products in the country. The other was the relaxation of the World Trade Organization's agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which permitted Bangladesh to reverse engineer-patented generic drugs. The relaxation of TRIPS for least developed countries has been extended to 2032 Bangladesh's pharmaceutical sector can grow at 15 percent for the next five years riding on the expanded domestic market as well as new export frontiers.

Pharmaceuticals industry has been one of the success stories of Bangladesh in the last three decades. Bangladesh had to depend largely for medicines on multinational companies and imports in the 1970s and early 80s. Now local companies meet almost 98 percent of domestic demand worth around USD 2 billion or Tk.16,000 crore. Domestic market of Pharmaceutical products in Bangladesh has shown an increasing trend over the past few years and the market size is increasing day by day. According to Bangladesh Association of Pharmaceutical Industries (BAPI) and Directorate General of Drug Administration (DGDA), approximately 257 licensed pharmaceutical manufacturers are operating in Bangladesh and about 150 are functional. These manufacturing companies meet around 98% of local demand.

Indo-Bangla Pharmaceuticals Ltd. has passed a successful year, during the year 2018-2019 we pleased with our overall performance of pharmaceutical business and believe that our endeavor and teamwork have enable the company to maintain its profitability under competitive industry picture. However, the company increased its net turnover to

Tk. 80,743,083 Crores up to by 12.24% from the previous year. This increase has been possible due to utilization of expansion capacity, use of new infrastructure with GMP facilities, manufacturing of more sophisticated new products having high profit margin, good management policies for reducing the overall manufacturing cost as well as our management team who are working for a better future for our stakeholders, buyers, employees and society at large.

At this occasion, I would like to thank the employees, without their efforts and commitments we would not have earned such a strong business position. Moreover, the production has been increased significantly over the years, which is main cause for keeping the fixed manufacturing cost at the minimum level by procuring raw materials from proper sources. The Net Profit after Tax has increased to Tk. 56,732,690 Which 57.60% higher than the previous year. In 2018-2019, the Company has maintained its growth in Profit comparing to the previous year. It is anticipated that positive momentum will continue in the coming year. Based on performance and business results the Board has recommended 9% Bonus Share (Stock dividend) in view to utilized its retained amount as capital for business expansion as well as working capital and 2% cash totaling 11% for the year 2018-2019.

You will be happy to know that, Indo-Bangla Pharmaceuticals Ltd. has undertaken courageous steps in setting up of a new production plant at kaliakoir, Gazipur. In this connection 145.43 decimal of land at 1st phase out of 1028 decimal Land for which bayna deed was made earlier has been registered as well as conceptual designs of new project has been started and civil work will be started by November, 2019 in order to meet increased demand of existing products as well as to achieve long term sustainable growth by including new technology and produce new generation drugs.

Toll Manufacturing Agreement with NIPRO JMI Pharma Ltd. has been completed for contract Manufacturing of Antibiotic, Cephalosporin and Penicillin products on behalf of Indo-Bangla Pharmaceuticals Ltd. to meet increased demand of existing products and to introduce new products.

The Board of Directors has decided to sign Manufacturing Agreement with RHK GLOBAL (hk) Limited. by this agreement Indo-Bangla Pharmaceuticals Limited will be produced Super Tramex-100mg brand Tablet (Generic Name: Tramadol Hydrochloride) at Indo-Bangla Pharmaceuticals Ltd.'s production plant, College Road, Barisal, Bangladesh. As per agreement Indo-Bangla will produce 1200 million Tablets/p.a. and the revenue of which is projected to be BDT 600 million/p.a.

IBPL is striving to upgrade and adopt new technology in production, quality control, distribution and administration of its products to produce new generation drugs as the faster growth of new and lifesaving drugs to customers/patients. the company invested a substantial amount in improving its Laboratory facilities, R&D Scale-up facilities etc.

The Board of Directors of IBPL aims to assure the integrity of business operations through rigorous processes and systems. We are committed to upholding the highest ethical standards while carrying out our business activities, and ensuring that consumer and patient safety is always a priority in our decision making. Every employee of the Company embeds the IBPL values of Integrity, Respect for People, Patient Focus and Transparency into their everyday work life.

Indo-Bangla Pharmaceuticals Ltd. truly believes that its people are its most valuable assets. Accordingly, the Company continued its programs for development of its human resources being the key contributor to Company's success. We value the contributions of our employees to the organization and adopted policy to reward them accordingly.

I would like to promise you that, our hard effort to increase the company's growth, wealth as well as to maximize the shareholder's equity will continue as before. Our effective and efficient management with skilled labor stands the main value drivers force of company. We strongly believe that the growth of the company, market stability as well as exercise good corporate governance of the Company will gradually rise in future by utilizing our optimum capacity through better corporate strategy.

I conclude by expressing my thanks to all employees of IBPL for the hard work they have put in during the last year. On behalf of the Board, I convey my sincere appreciation to our valued Business Partners, the Healthcare Professionals and Institutes, Suppliers and Government Authorities for their trust and continued support to the Company.

Finally, I pray to Almighty Allah to bless us with success and help us in our endeavor marching towards a bright future and benevolence to our people as a whole.


A F M Anwarul Huq
Managing Director.

B. ROLE & RESPONSIBILITIES OF THE BOARD:

The Board is responsible for the strategic direction, policies and overall management of the Company. The Board is to provide general superintendence, oversee policies and overall management of the Company. The operations and control the affairs of the company through appropriate delegation and accountability processes via the lines of command. It ensures that the Company's policies and activities conform to Mission, Key goals and a Core values. Code of Conduct, Key strategies, Policies and Practices as set out in the statements of policies, safeguarding the assets of the Company and establishing an adequate as well as effective system of internal control. The Board has authorized the formation of a number of Committees to implement the stated policies and activities. The Committees are: Audit Committee, NRC Committee. The Audit Committee ensures that adequate internal checks & balances supported by adequate MIS are in place for detection of errors frauds and other deficiencies. The other responsibilities include inter alia, not being limited to, the prevention of conflict of interest between the company and its Directors officials, customers, suppliers, government and any other interest groups and detect or remove any scope of insider trading in the company's stock. The Audit Committee also ensures compliance of requirements of BSEC and other agencies. The details about Audit Committee including composition, responsibilities, meetings, reporting and activities carried by the Audit Committee is disclosed in the Annual Report in "Report of the Audit Committee".

C. FREQUENCY OF THE MEETING:

The Board meets at least a quarter. The number of meetings that were held during the financial year ended 30 June, 2019 was 11.

D. RELATIONSHIP WITH SHAREHOLDERS & PUBLIC:

The shareholders as owners, are required to be provided with material information on the company's operation quarterly, half-yearly and annually, the latter at the AGM. They are also provided routine services by the Company Secretary in matters of transfer of shares, replacement in case of loss or damage of shares, payment of dividends etc. The Board is however responsible to the public for publication of any price sensitive information as per BSEC regulation.

E. RELATIONSHIP WITH SUPPLIERS:

As the company has to import plant and machinery and almost all the raw materials from abroad, it maintains cordial and mutually beneficial interest with its international as well as local suppliers. This has enabled the company to avoid any legal disputes in international/local courts and enhanced the company's image as a good customer.

F. CORPORATE SOCIAL RESPONSIBILITIES (CSR):

The Board of Directors is also awoken of the Corporate Social Responsibilities (CSR) especially in the areas of gender equality, race, religion, regional equality, non-employment of child labour, human rights, environmental pollution, social-marketing, social activities (promotion of sports & culture, health care and population control programs, elimination of corruption programs, participation in charitable activities etc. in non-partisan manner) right to form and participate in Union under ILO convention, employment of disabled etc.

DISTINCTIVE ROLE OF THE CHAIRMAN & MANAGING DIRECTOR

The positions of Chairman of the Board and the Managing Director of the Company are filled by different individuals who are member of the Board. The Chairman of the Board elected from the non-executive directors of the company.

CHIEF FINANCIAL OFFICER, HEAD OF INTERNAL AUDIT AND COMPANY SECRETARY FILLED BY DIFFERENT INDIVIDUALS.

The Company has appointed Mr. Md. Faruque Hossain as Chief Financial Officer, Mr. Mohi Uddin, QCS as Company Secretary and Mr. Md. Abu Taleb as Head of Internal Audit of the company as per requirement of Bangladesh Securities and Exchange Commission (BSEC).

BOARD OF DIRECTOR'S COMMITTEE: AUDIT COMMITTEE-

The Board has formed an Audit Committee of the Board consisting of three (3) member to assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and ensuring a good monitoring system within the business.

The Audit Committee carries out its responsibilities as per the provisions of law and submits its report to the Board of Directors from time to time. The Audit Committee shall also co-ordinate with the Internal and external Auditors as and when required. The Audit Committee ensures that adequate internal checks & balances supported by adequate MIS are in place for detection of errors frauds and other deficiencies. The other responsibilities include inter alia, not being limited to, the prevention of conflict of interest between the company and its Directors officials, customers, suppliers, government and any other interest groups and detect or remove any scope of insider trading in the company's stock. The Audit Committee also ensures compliance of requirements of BSEC and other regulatory.

MEMBERS OF AUDIT COMMITTEE.

The Board has established a committee of the Board known as the Audit Committee consisting of three (3) members to assist the Board

Chairman	S. M. Harun Or Rashid
Members	Md. Amin-Ur-Rashid Mrs. Fatima Parvin
In attendance	
Secretary	Mohi Uddin, Company Secretary

Mr. Mohi Uddin, QCS Company Secretary is the Secretary to the Audit Committee. The number of the meeting held during year ended June 30, 2019 were 4 (four)

The details of the Audit Committee including background, composition, responsibilities, meeting, reporting and activities carried out by the Audit Committee is disclosed in this Annual Report in "Report of the Audit Committee".

NOMINATION & REMUNERATION COMMITTEE

The Board has formed a Nomination & Remuneration Committee of the Board consisting of three (3) member to assist the Board in formulation measures policy for determining qualifications, positive attributes, experiences and independence of director and top level executives.

The Nomination and Remuneration Committee shall assist the Board in formulation of the nomination criteria for a policy for formal process of considering remuneration of directors and top level executives

MEMBERS OF NOMINATION & REMUNERATION COMMITTEE.

The Board has established a committee of the Board known as the Nomination & Remuneration Committee consisting of three (3) members to assist the Board

Chairperson	Md. Monirujjaman.
Members	Mrs. Sayeda Huq. Md. Mizanur Rahman
In attendance	Chairman Managing Director External Advisers – by invitation Any Non-Executive Director shall be entitled to attend the Committee's meetings.
Secretary	Mohi Uddin, Company Secretary

Mr. Mohi Uddin, QCS Company Secretary is the Secretary to the nomination & Remuneration Committee. The number of the meeting held during year ended June 30, 2019 were 1(one)

INDEPENDENT DIRECTOR:

In compliance with the BSEC Notification on Corporate Governance Code, the Board of Directors as empowered by the Regulations, appointed Mr. S.M Harun Or Rashid, former official of Government, Mr. Md. Monirujjaman an Advocate of Supreme Court of Bangladesh and Mr. Feroj Khan, Director of Sabila Sea Foods Ltd. Appointed as Independent Director.

LEGAL ADVISERS:

In order to avail the best legal services for Good Corporate Governance, the company has appointed Mr. shahadat Hossain. to support the Company's Good Governance efforts.

AUDITORS:

The role of the auditors in certification of the financial statement is the most significant aspect of Corporate Governance and protection of interest of investors. As evident from the Annual Reports, the company rigidly follows the code of International Accounting Standards (IAS) and International Standard of Auditing (ISA) with legally required disclosures of Accounts and Financial Statements. This has been possible due to the high level capability and integrity of **M/s. Mahfel Huq & Co.**, Chartered Accountants whose unchallenging performance has played a very trustworthy role in the protection of interest of the investors.

INTERNAL AUDIT AND CONTROL:

The Indo-Bangla Pharmaceuticals Limited. Considers that internal audit is one of the important regular function of the Company. The Company has an independent internal audit department under control of the Audit Committee of the Board. Department of Internal Audit and Control gives effort to bring a methodical disciplined approach to evaluate and improve the effectiveness of the organization's risk management process, system of the internal control and governance.

COMPLIANCE AUDIT

In order to make sure the integrity to the corporate governance with accountability for inspiring the confidence of investors, regulators, financier and other stakeholder. Indo-Bangla Pharmaceuticals Ltd. is committed to maintain the compliance with the requirements of the Corporate Governance Code issued by the BSEC.

The certificate for the compliance status of Indo-Bangla Pharmaceuticals Ltd. On the condition of Corporate Governance Code audited by Shafiq Basak & Co. Chartered Accountants is attached herewith on page no. 51 of this Annual Report.



Since 1954 Indo-Bangla is working for the healthcare development of Bangladesh to ensure health, heartiness and happiness for mankind.

www.indo-banglapharma.com



WE OFFER

Indo- Bangla Pharma currently produces more than 90 brands and applied for 11 new Brand. Indo-Bangla Pharma's portfolio encompasses various the categories, including analgesics, respiratory, cardiovascular, central nervous system, dermatology, gastrointestinal etc. The company has sound expertise with specialized and advanced drug delivery systems that have created strong differentiation. Many of its brands remain consistent leaders in their respective therapeutic categories and the company continuously reviews and expands its product portfolio in order to ensure that people have access to newer, better treatment options at affordable cost. The expanding portfolio, including high value, differentiated, and difficult to copy products will continue to drive strong growth in the coming days.



MANUFACTURING CAPABILITIES

In line of International standards, our state of the manufacturing facilities is spread across a 37.40 decimals area located near the heart of Barisal city, Barisal, which houses facilities for manufacturing tablets, capsules, intravenous fluids, liquids, suppositories, injectable as well as the bulk paracetamol production unit. There are also water purifying and liquid nitrogen generation facilities. Currently being Constructing with large capacity to provide to the emergent demand.



Total Quality Management

QUALITY COMPLIANCE:

To preserve and improve patient health by consistently delivering high quality, safe and effective specialty pharmaceutical products and services, that meet or exceed customer expectations. IBPL is committed to successful deploying our company's Quality Policy to all aspects of our activities - assuring continued high quality, usefulness and effectiveness of products for our customers. Having an experienced workforce, equipped with continuing education and training in emerging Quality techniques and philosophy.

QUALITY CONTROL:

We have a separate Galenical laboratory for R & D, equipped with all the necessary machineries & equipment of current GMP standard in small scale for the team to develop products.

IBPL Quality Control Department guide and support in analytical development. Quality Control Department is equipped with highly sophisticated instruments like UPLC, Gas Chromatography, Atomic absorption spectrophotometer, FTIR, etc. A highly sophisticated microbiology laboratory has been setup to cater to the need for quality control of regular products as well as control of all the different biological products that the company produces.

RESEARCH & DEVELOPMENT

"As commitment to discovery and development of drug, IBPL has an ironic and unique pipeline that is persistently surfacing."

A part from the hundreds of different drug contenders and new technologies under our investigation in our laboratories, we significantly identify and strictly prioritize those with the greatest potential to deliver newstandards of care-critical for our commitment to produce the best therapies.

our intent to develop drugs that accurately target biological processes in patients with specific disease profiles, with companion diagnostics to identify those people who will receive most benefit.

We proactively utilize external resources and specialist excellence at every stage of the R&D process – enabling us to deliver as many innovative new drugs as possible. In the drug discovery & development phase, we partner and collaborate with public and private organizations to harness complementary capabilities to medicalscience.



OUR PEOPLE

Indo-BanglaPharmaceuticals' success and accomplishments story lies on 219 strong & skilled workforces, who have stood by the company through thick and thin. The IBPL workforce is charged with the life-force from highly skilled and dedicated professionals. People are our most valuable assets and we always recognize that the the essence of this company and their collective resolve to excel- will propel us forward to reach new heights. We seek to provide a workplace that inspires people to be the best they can be. Our ability to transform ourselves is driven by a strong emphasis on employee empowerment at every level.

PRODUCT MANAGEMENT:

The Product Management Department lies in the center of all marketing activities. A dedicated team with excellent professional background comprising Pharmacists, Biochemists, MBAs and Microbiologists work in this department. They formulate the strategies to uphold the market share of company's products, select and introduce new products to keep the company growing and develop promotional materials for the sales people to win in the market.

MARKETING:

The marketing Department plays an important part, as they do the implementation part of all strategies. A large team with highly skilled sales people work throughout the country to bring in success for the company. Team spirit remains as the key to success of the sales department of Indo-Bangla Pharmaceuticals Ltd.



CORPORATE SOCIAL RESPONSIBILITIES

As our strategic commitment; corporate social Responsibility (CSR) is an integral part of our company and continually guided by ethical values to operate responsibly in socio-economic context. We truly believe one can only be affluent if one generates value not just for the company but also for the society. We contribute to society by supporting the communities to achieve sustainability and growth by improving the health and well being.

The company believes in enriching the lives of people by providing innovative high quality medicines with affordable price. We strongly believe in stirring the lives of people of employees by giving them the scope of growth and achievement, providing fair employment conditions and having a safe & health environment.

We support charitable projects in area of healthcare through Rotary, support various Mosque, School and NGOs in selected programs, arrange & participate medical camps and consistently reach out beyond the boundaries of our company to touch societies in which we work. We assist and provide aid in the event of disasters and other emergency situations.

We demonstrate our commitment towards environment by following environment friendly practices across the organization and ensuring manufacturing facilities continuously reducing impact on the environment.

PRODUCT PORTFOLIO

Major Products



Group	Trade Name	Generic Name
Antiulcerants & Antacids	 Protobit-20	Omeprazole BP (Enteric Coated Pellets)
	Tablet Trialugel 250mg & 400 mg	Aluminium Hydroxide Dried Gel BP Magnesium Hydroxide BP
	 ParamolPlus 500mg & 65mg .	Paracetamol BP Caffeine BP
	Tablet Paracetamol 500mg	Paracetamol BP
	Suspension Paramol	Paracetamol BP
		
Antifilariasis	Tablet Indo -Fila 100mg	Diethylcarbamazine Citrate BP
Antihistamine & Antiallergic Preparations	Elixir Arromin	Promethazine Hydrochloride BP
	Tablet I -Cet 10mg	Cetirizine Hydrochloride BP
	Syrup I -Cet	Cetirizine Hydrochloride BP
	Elixir Arromin	Promethazine Hydrochloride BP
	Tablet Indosin	Chlorpheniramine Maleate BP
	Syrup Indosin	Chlorpheniramine Maleate BP

Group	Trade Name	Generic Name
Anti -Anaemia	Syrup Auriotone	Ferrous Sulphate BP
	Capsule I Need Z	Ferrous Sulphate, Folic Acid, Zinc Sulphate USP
	Tablet I -Fol	Ferrous Fuma rate & Folic Acid
	Tablet I -Fol Plus	Ferrous Fumarate & Folic Acid
	Syrup Auriotone	Ferrous Sulphate BP
	Capsule I Need Z	Ferrous Sulphate, Folic Acid, Zinc Sulphate USP
	Tablet I -Fol	Ferrous Fumarate & Folic Acid





Anthelmintic	Tablet Mebendox 100 mg	Mebendazole BP
	Suspension Mebendox	Mebendazole BP
	Tablet Albendox 400mg	Albendazole USP
Anti-Asthmatic Preparations	Syrup Sulbumol	Salbutamol Sulphate BP
	Tablet Sulbumol 2.0mg	Salbutamol Sulphate BP
	Tablet Sulbumol Plus 4.0mg	Salbutamol Sulphate BP
	Tablet Indophylline 100mg	Aminophylline BP



Group	Trade Name	Generic Name
Macrolides	Capsule Indoith 250mg	Azithromycin Dihydrate USP
	Tablet Indoith 500 mg	Azithromycin Dihydrate USP
	Indoith Powder for Suspension	Azithromycin Dihydrate USP
Quinolones	Tablet Cipro -I 750mg	Ciprofloxacin Hydrochloride USP
	Tablet Cipro -I 500mg	Ciprofloxacin Hydrochloride USP
Penicillins	Indomoxin Powder for Suspension	AmoxycillinTrihydrate BP
	Capsule Indoflox 250mg	AmoxycillinTrihydrate BP
	Capsule Indoflox 500 mg	AmoxycillinTrihydrate BP
	Indoflox Powder For Suspension	AmoxycillinTrihydrate BP
	Indomoxin Powder for Paediatric Drops	Flucloxacillin Sodium BP
	Capsule I -Cillin 250mg	Flucloxacillin Sodium BP
	Capsule I -Cillin 500mg	Flucloxacillin Sodium BP
	I-Cillin Powder for Suspension	AmoxycillinTrihydrate BP
Penicillins	Tablet Indomox250mg	AmoxycillinTrihydrate BP
	Capsule Indomoxin250mg	AmoxycillinTrihydrate BP
Tetracycline Group of Drugs	Capsule Indotetra500mg	Tetracycline Hydrochloride BP
	Capsule Indox	Doxycycline Hydrochloride BP
Sulphonamides	Tablet Cotrimox400mg & 80mg	SulphamethoxazoleBP Trimethoprim BP
	Tablet Cotrimox-DS 800mg & 160mg	SulphamethoxazoleBP Trimethoprim BP
	Suspension Cotrimox	SulphamethoxazoleBP Trimethoprim BP
Cephalosporins & Cephameycins	Capsule Indocef	Cephradine Monohydrate BP
	Indocef DS Powder for Suspension	Cephradine Monohydrate BP
	IndocefPowder for Suspension	Cephradine Monohydrate BP
	IndocefPowder for Paediatric Drops	Cephradine Monohydrate BP
Gastroprokinetic & Antiemetic Preparations	Tablet I-Pedom 10mg	Domperidone Maleate BP
	Suspension I-Pedom	DomperidoneBP





Antifungal (Dermatological) Preparations	Tablet Gylfusin 500 mg	Griseofulvin BP
Antiprotozoal Preparations	 Tablet Metrol 200mg	Metronidazole BP
	Tablet Metrol 400 mg	Metronidazole BP
	Suspension Metrol	Metronidazole Benzoate BP
Bone Calcium Regulator	Tablet Caltab 300 mg	Calcium Lactate BP
	Tablet Indocal 1250 mg	Calcium Carbonate BP
Cough Expectorant	Syrup Indocof	Dextromethorphan Hydrobromide BP Pseudoephedrine Hydrochloride BP Triprolidine Hydrochloride BP
Vitamins & Minerals	Tablet Indocal -D	Calcium Carbonate & Vitamin D 3
	Tablet Calfresh -M	Calcium Carbonate BP, Vitamin D3, Magnesium Oxide BP, Zinc Oxide BP, Cupric Oxide Ph.Gr., Manganese Sulphate Monohydrate BP, Boron Citrate Ph.Gr.
Urinary Anti -Infective	Tablet Naldic 500mg	Nalidixic Acid BP
Non-Hormone Sex Stimulant Drugs	 Tablet Makmaul Sanagra -100mg	Sildenafil Citrate BP

CORPORATE OPERATIONAL RESULTS

Summary of key operating and financial data for the least preceding 5 (Five) years are as follows:

Financial Highlights.



Operational Result	Amount in Taka				
	2018-19	2017-18	2016-17	2015-16	2014-15
Turnover	740,714,183	659,971,100	616,711,210	444,777,724	435,024,108
Gross Profit	296,550,952	260,400,732	234,910,917	182,248,732	177,140,449
Profit from Operation	178,281,873	153,178,111	132,222,600	94,497,109	92,419,984
Net Profit before tax	180,778,346	151,529,230	135,957,956	90,807,238	92,629,642
Net Profit after Tax	155,226,689	98,493,999	88,372,671	59,024,705	60,209,267
Net Operating Cash Flow per Share	1.70	1.20	1.09	0.19	7.56
Financial Position	2018-19	2017-18	2016-17	2015-16	2014-15
Non-Current Assets	918,753,321	654,019,821	536,553,973	330,469,857	158,274,850
Current Assets	666,994,351	565,947,614	541,115,957	614,908,956	224,744,682
Shareholder's Equity	1,374,627,332	1,036,100,643	937,606,643	849,233,972	159,209,267
Current Liability	144,361,259	116,617,191	101,883,096	82,321,162	219,787,471
Non-Current Liability	66,759,081	67,249,601	38,180,191	13,823,879	4,022,794
Key Financial Ratio	2018-19	2017-18	2016-17	2015-16	2014-15
Current Ratio	4.62	4.85	5.31	7.47	1.02
Quick Ratio	2.36	2.40	2.75	4.29	0.22
Debt to Equity Ratio	-	-	-	-	-
Net Income Ratio (%)	20.96	14.92%	14.33%	13.27%	13.84%
Return on Equity (%)	12.88	9.98%	9.89%	11.71%	37.82%
Earnings Per Share	1.58	1.35	1.21	2.62	6.40

DIRECTOR'S REPORT TO THE SHAREHOLDERS

to the Members for the 12th months period ended 30 June, 2019

Bismillahir Rahmanir Rahim

Distinguished Shareholders,

Assalamu Alaikum Wa Rahmatullahi Wa Barakatuhu,

In terms of provisions of section 184 of the Companies Act 1994, Rule 12 (and the Schedule there under) of the Bangladesh Securities and Exchange Rules, 1987, BSEC Notification dated 3 June, 2018, IAS-1 (International Accounting Standard-1) and Finance Act The Board of Directors of Indo-Bangla Pharmaceuticals Ltd. take the pleasure in presenting the Audited Financial position, Statements of Profit or Loss & other Comprehensive Income, Statement of Cash Flows and Statement of Changes in Equity for the reporting period ended June 30, 2019 along with the Auditors Report thereon for your valued consideration in the following paragraph:

BACKGROUND

Indo-Bangla Pharmaceuticals Limited (IBPL) was incorporated with the Registrar of Joint Stock Companies and Firms (RJSC) on June 18, 2014 and was converted into a Public Limited Company on October 21, 2014 under the Companies Act, 1994. The Company went for Initial Public Offering & consent date of BSEC the 19 February, 2018, issue date of Prospectus March 13, 2018. The Company was listed with Dhaka Stock Exchange Limited (DSE) on 23rd September 2018 and Chittagong Stock Exchanges Limited (CSE) on 30th September 2018. The Trading date with Exchanges October 18, 2018 The Authorized capital of the company is Tk. 1,500 million and paid-up capital 1023 million as at June 30, 2019

INDUSTRY OUTLOOK AND POSSIBLE FUTURE DEVELOPMENT OF THE COMPANY. OVERVIEW

The pharmaceutical industry in Bangladesh is one of the most developed sectors within Bangladesh. Manufacturers produce insulin, hormones, and cancer drugs. This sector provides 98% of the total medicinal requirement of the local market. The industry also exports medicines to global markets, including Europe. Pharmaceutical companies are expanding their business with the aim to expand the export market. The Pharmaceutical sector of Bangladesh has been transforming and evolving since the early 80s. The sector has grown from strength to strength over the last 4 decades. Since this is a technology and knowledge based sector; the journey was not an easy one for a LDC country faced with enormous economic challenges. Now, Bangladesh proudly stands alone as the only LDC that has a well-developed pharma sector.

PHARMACEUTICAL INDUSTRY BLOOMS BIGGER

The country's domestic pharmaceutical market size stood at Tk. 20,511.8 crore with 15.6% compound annual growth rate (CAGR) for the last five years. Once largely dependent on imports and multinational companies to meet the local demand, Bangladeshi pharmaceutical industry is growing very fast meeting 98% of domestic demand and posting a 27% growth in export earnings. On top of that, the sector is expected to grow at 15% year-on-year to reach \$5.11 billion by 2023, propelled by high investment by local companies as they seek to grab a bigger share of the global market.

Bangladesh's economy is growing at over 8% per annum with increased per capita income of \$1909, while life expectancy increased to 73 years, Life expectancy of people has significantly increased — the average life expectancy of 66.4 years in 2002 rose to 72.81 years in 2018. Improved healthcare facilities and diagnosis with modern technology and rapid growth of chronic diseases due to change in lifestyle and environment factors are other reasons for the growth of domestic drug market.

AT A GLANCE

- Domestic market size Tk20,512 crore
- Annual growth 15.6%
- Local companies hold 90% market share
- Multinationals hold 10% share
- 98% demand met locally, 2% with exports
- Contributions to GDP 1.83%
- 80% makers produce generic drugs
- 20% manufacture patented drugs
- Bangladesh exports to 147 countries



EXPORTS OPEN NEW AVENUES FOR BANGLADESH

Global certification and adoption of new technologies along with efforts to make local medicine familiar abroad and cash incentives against exports of medicine are the key reasons for the sharp rise in exports earnings. According to Export Promotion Bureau (EPB) data, Bangladesh's medicine exports registered a 25.60% rise to \$130 million in FY19, which was \$103.46 million the previous year. The export earnings to a new high, exports to the United States of America played an important role and it is a great achievement and milestone for Bangladesh. According to Bangladesh Association of Pharmaceutical Industries (BAPI), approximately 1,200 pharmaceutical products received registration for export in the last two years.



SCOPE TO GROW IN FUTURE...

According to Business Communications Company (BCC) Inc, a US-based research organization, the global market for generic drugs is expected to reach \$533 billion by 2021 from \$352 billion in 2016 at a compound annual growth rate (CAGR) of 8.7%.

"Bangladesh is going to be a major global hub for high quality low cost generic medicine and vaccine. In reaping the benefits, Bangladesh needs to develop the knowledge and capacity to grab a bigger share of the global pharmaceutical market. Local drugs manufacturers of Bangladesh mainly produce generic drugs of the total amount, 80.0% are generic and 20.0% patented drugs.

INDO-BANGLA LOOKS FOR A BRIGHT FUTURE

Indo-Bangla Pharmaceuticals Ltd, is a reliable name in the pharmaceuticals sector of Bangladesh, works relentlessly to move forward with a targeted vision to be on the forefront of changing healthcare environment turning innovative science towards esteemed new treatment preferences.

Indo-Bangla steps forward with the pre-determined vision to achieve excellence in manufacturing and marketing of pharmaceuticals products and trying to extending its business in abroad as well.

New technology, new invention, new products as well as new project are the rhythm of life of pharmaceuticals Company. Since, Indo-Bangla Pharmaceuticals Ltd. is well aware of the adoption new technology and has taken a number of ambitious initiatives and business strategy to meet the upcoming challenges:

TOLL MANUFACTURING AGREEMENT

Toll Manufacturing Agreement with NIPRO JMI Pharma Ltd. Dhaka, Bangladesh has been completed for contract Manufacturing of Antibiotic, Cephalosporin and Penicillin products on behalf of Indo-Bangla Pharmaceuticals Ltd. to meet increased demand of existing products and to introduce new products.

List of Products mutually agreed to be manufactured by NIPRO JMI Pharma Ltd. are as follows: Azithromycin-500mg, Ciprofloxacin-500mg, Amoxicillin-250mg, Amoxicillin-125mg, Amoxicillin-500mg, Flucloxacillin-250mg, Flucloxacillin-125mg, Cephadrine-500mg, Cephadrine-125mg, Azithromycin-200mg.



Toll Manufacturing Agreement Between Indo-Bangla Pharmaceuticals Ltd and NIPRO JMI Pharma Ltd.

EXPORT ACTIVITIES

The Company is giving utmost effort to enter the Export Market in addition, demands for generic medicine in the global market, Indo-Bangla Pharmaceuticals Ltd. has decided to drive to penetrate export markets, in this connection the Board of Directors of Indo-Bangla Pharmaceuticals Ltd. has decided to sign Manufacturing Agreement with RHK GLOBAL (hk) Limited. With its registered office at 1/F Mau Lam Commercial Building, 1st Floor, 16-18, Mau Lam Street, Jordon, Hong Kong. By this agreement Indo-Bangla Pharmaceuticals Limited will be produced Super Tramex-100mg brand Tablet (Generic Name: Tramadol Hydrochloride) at Indo-Bangla Pharmaceuticals Ltd.'s production plant, College Road, Barisal, Bangladesh. As per agreement Indo-Bangla will produce 1200 million Tablets/p.a. and the revenue of which is projected to be BDT 600 million/p.a. subject to approval from The Directorate General of Drug Administration (DGDA) under the Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh, is the Drug Regulatory Authority of the country as Pharmaceuticals Company of Bangladesh can only sell different medicine to other country when they get approval of the particular medicine from the drug authority of that particular country. Since the sector is very sophisticated and sensitive, manufacturers of medicine have adopted modern technology, which is hugely contributing to the growth of pharmaceuticals industry of Bangladesh both in domestic and exports markets. In recent time, the Government of Bangladesh has given huge emphasis on the export of Pharmaceutical products from Bangladesh. It is targeted that Pharmaceutical will be the second exporting product after readymade garments. The Government of Bangladesh has set up an export target.

NEW PROJECT, KALIAKOIR, GAZIPUR.

You will be happy to know that, in order to meet increased demand of existing products as well as to achieve long term sustainable growth of the Indo-Bangla Pharmaceuticals Ltd. by including new technology and produce new generation drugs, Indo-Bangla Pharmaceuticals Ltd. has undertaken a courageous step in setting up of a new production plant at kaliakoir, Gazipur. In this connection 145.43 decimal of land at 1st phase out of 1028 decimal Land for which bayna deed was made earlier has been registered as well as conceptual designs of new project has been started and civil work will be started by November, 2019.

NEW TECHNOLOGY

Indo-Bangla Pharmaceuticals Ltd. is striving to upgrade and adopt new technology in production, quality control, distribution and administration of its products to produce new generation drugs as the faster growth of new and lifesaving drugs to customers/patients During the year (2018-2019). the company invested a substantial amount in improving its Laboratory facilities, R&D Scale-up facilities etc.

RISK AND CONCERNS

Different types of risk and concern in Pharmaceuticals industries are- Tariffs and international trade restrictions, Insufficient raw material production facilities, Absence of bioequivalence test facility, Lack of modern drug testing laboratory.

Marketing strategy- Pharmaceutical industries are now in high-end development trend that is being carried out by leading companies. Increasingly, many companies are competing with new pharmaceutical industries. As a result, the success of pharmaceutical industries largely depends on the efficiency and effectiveness of the highly trained and qualified medical promotion officers.

Problems regarding export, Contest in the Bangladeshi pharmaceutical market, Rivalry among existing firms, Threat of new entrants, Threat of substitute products, bargaining power of buyers, Bargaining power of suppliers.

Changes in the existing global or national policies can have either positive or negative impacts for the company. Any insufficiency or price hike of raw materials due to change in policy in the international market might hamper the production and profitability. Changes in currency exchange rates might also affect the pricing and thereby the profitability of the Company.

Similarly, risks factors of the industry depend on the Government polices as well. However, the industry is also exporting abroad. Currently, formulations are exported to 92 countries around the world. The major destinations for Bangladeshi medicines are Myanmar, Sri Lanka and Kenya, while nearly 50 countries import Bangladeshi medicines regularly.

OPERATIONS AND STATE OF AFFAIRS OF THE COMPANY:

FINANCIAL RESULTS

The operating financial results of the Company for the year 2018-2019 as compared to previous year are summarized hereunder:

Particular	2018-2019	2017-2018	% Increase
Turnover	740,714,183	659,971,100	12.24%
Gross Profit	296,550,952	260,400,732	13.88%
Financial Expenses	-	-	-
Non-Operating Income	11,535,389	5,927,580	94.61%
Net Profit Before Tax (NPBT)	180,778,345	151,529,230	19.30%
Provision for Taxation	25,551,656	53,035,230	(51.63%)
Net Profit After Tax (NPAT)	155,226,689	98,493,999	57.60%%
Gross Margin (Turnover)	40.04%	39.46%	1.46%
Net Margin Before Tax	24.41%	22.96%	6.30%
Net Margin After Tax	20.96%	14.92%	40.46%
Earnings Per Share (EPS) BDT.	1.58	1.20	31.67%

The Gross Profit, Operating Profit and Net Profit (BT) increased during FY 2018-19 at 13.88%, 16.39% and 19.30% respectively over the previous year. However, the Cost of Goods Sold increased at 11.16% over previous year which helped increase Gross Profit and Operating Profit of The Company. The Net Profit (AT), however, increased by 57.60% over the previous year.



The Earning per Share of Tk. 1.58 is the basic earning dividing by the weighted average number of shares outstanding at the end of the Period.

DISCUSSION ON EPS & NOCFPS

The Company's Standalone Revenues from operations were TK. 740.72 million for the year ended 30th June, 2019 as compared to TK. 659.97 million for the previous year, an increase by 12.24%

The company has made Net Profit of TK. 155.23 million on standalone basis for the year under review as compared to TK. 98.49 million for the previous year.

Earnings Per Share (EPS) of Tk. 1.58, NAV per share of Tk. 13.44, and NOCFPS of Tk. 1.70 for the year ended on June 30, 2019 as against Tk. 1.20, Tk. 14.19 and Tk. 1.06 respectively for the same period of the previous year.



DISCUSSION ON COST OF GOODS SOLD, GROSS PROFIT MARGIN, AND NET PROFIT MARGIN SHOWN BELOW:

Profit from Operation	30-June-19		30-June-18	
	Amount	Percentage	Amount	Percentage
Turnover	740,714,183	100.00	659,971,100	100.00
Cost of Goods Sold	444,163,230	59.96	399,570,368	60.54
Gross Profit	296,550,952	40.04	260,400,732	39.46
Net Profit for the year	155,226,689	20.96	98,493,999	14.92




APPROPRIATION OF PROFIT.

The Board of Directors recommended the appropriation of the net profit earned during the year 2018-2019 in the following manner:

A. Net Profit for the year (2018-2019)	Tk. 155,226,689
B. Appropriation Proposed:	
(i) Cash Dividend @ 2% (Tk.0.20 per share)	13,272,820
(ii) Stock Dividend @ 9%, face value of Stock Dividend (Bonus Share)	92,070,000
	105,342,820
C. Net Un appropriate Profit	49,883,869

DIVIDEND

The Company has invested a substantial amount for expansion of capacity as well as diversification of products and business. However, the Board of Directors at its Board meeting held on 28 October, 2019 has recommended 2% Cash Dividend for all general shareholders and ICB (excluding Sponsor/Directors) and 9% Stock Dividend for all shareholders for the year ended on June 30, 2019 the Sponsors/Directors hold 3,59,35,900 shares out of total 102300000 shares of the Company and the cash Dividend to be payable to the General Shareholders of TK. 13.273 million.



SEGMENT WISE REPORTING

The company operates only in one segment, which is manufacturing and selling of all kinds of medicine (excluding Antibiotic), medical preparations drugs & chemicals (Human Health). The Company applied for permission for production and selling of veterinary medicine also.

DISCUSSION ON CONTINUITY OF EXTRAORDINARY GAIN OR LOSS

Extraordinary gains or losses refer to irregular and infrequent gain or loss and which is not part of the Company's ordinary/day to day operations. As for the Company, there was no such gain or loss during the year ended June 30, 2019

RELATED PARTY TRANSACTION

Related party transactions are presented in note no. 33 of the notes to the financial statements.

RELATED PARTIES TRANSACTIONS:

The company carried out a number of transactions with related parties. The following are the related parties transactions of the Indo-Bangla Pharmaceuticals Ltd has been disclosed as required by BAS 24 Related Party Disclosures.

(a) Remuneration

Name	Designation	Nature of Transaction	Amount in (BDT)	
			2018-2019	2017-2018
Mr. A.F.M Anowarul Huq	Managing Director	Remuneration	1800000	1,800,000

(B) BOARD MEETING FEE

Name	Designation	Nature of Transaction	Amount in (BDT)	
			2018-2019	2017-2018
Mrs. Aziza Yeasmin	Chairman	Board Meeting fee	50,000	50,000
Mr. A.F.M Anowarul Huq	Managing Director		55,000	50,000
Mrs. Hafiza Yeasmin	Director		20,000	50,000
Md. Amin-Ur-Rashid	Director		50,000	40,000
Sayeda Huq	Director		50,000	40,000
Fatima Parvin	Director		55,000	35,000
Mst. Shanaj Akter	Director		40,000	35,000
Mizanur Rahman	Director		50,000	35,000
Md. Golam Rabbani	Director (Represented of ICB)			20,000
S.M. Harun Or Rashid	Independent Director		50,000	20,000
Md. Monirujjaman	Independent Director		45,000	15,000
Md. Firoz Khan	Independent Director		40,000	15,000

STATEMENT OF UTILIZATION OF PROCEEDS RAISED THROUGH IPO

Indo-Bangla Pharmaceuticals Ltd. has received Tk. 200,000,000 (Taka Twenty Crore) only as Initial Public Offering (IPO) proceeds through subscription from 09 August to 16 August. And the expenses/utilization has been made in the line with the provision of Initial Public Offering (IPO).

The expenses/utilization Tk. 10,61,63,090 of IPO proceeds have been completed Nine (9) month (after the receiving of IPO fund) within 24 (Twenty-Four) months mentioned the time schedule/implementation schedule as specified Initial Public Offering (IPO) documents as well as the utilization made is accurate for the purpose of the Company as mentioned in Initial Public Offering (IPO) documents.

The breakup of Utilization Position of IPO proceeds up to 30 June, 2019 was as under:

Purpose as per prospectus	Amount as per Prospectus	Utilized during the year	Total Utilization
Construction and other civil works	58,580,000	-	-
Machineries	124,720,000	89,463,090	89,463,090
IPO expenses	16,700,000	16,700,000	16,700,000
	200,000,000	106,163,090	106,163,090

The company raised Tk. 200,000,000 divided into 20,000,000 ordinary shares of Tk. 10 each through IPO on September 13, 2018. The company utilized Tk. 106,163,090 in total up to June 30, 2019 for the purposes described above as certified by independent auditor, G. Kibria & Co, Chartered Accountants.

SIGNIFICANT VARIANCE OF FINANCIAL STATEMENTS

No significant variation occurred between quarterly and final results of the Company during the year ended June 30, 2019.

BOARD SIZE

The number of members of the Board of Directors stands at 12 (including Three Independent Director) which are within the limits given by the BSEC Notification.

SL	Name	Designation in IBPL
1	Aziza Yeasmin	Chairman
2	A F M Anowarul Huq	Managing Director
3	Hafiza Yeasmin	Director
4	Md. Amin-Ur-Rashid	Director
5	Sayeda Huq	Director

SL	Name	Designation in IBPL
6	Fatima Parvin	Director
7	Mst. ShahanazAkter	Director
8	Md. Mizanur Rahman	Director
9	Investment Corporation of Banglades Represented by Md. Golam Rabbani	Director
10	S.M. Harun Or Rashid	Independent Director
11	Md. Monirujjaman	Independent Director
12	Md. Firoz Khan	Independent Director

DIRECTORS INVOLVED IN OTHER COMPANIES

SL	Name	Designation in IBPL	Directorship/Ownership with Other Companies	
			Companies	Position
1	Aziza Yeasmin	Chairman	-	-
2	A F M Anowarul Huq	Managing Director	IBP Agrovot Ltd., Sabila Sea Foods Ltd. HBS Apparels Ltd.	-
3	Hafiza Yeasmin	Director	-	-
4	Md. Amin-Ur-Rashid	Director	-	-
5	Sayed a Huq	Director	-	-
6	Fatima Parvin	Director	-	-
7	Mst. ShahanazAkter	Director	-	-
8	Md. Mizanur Rahman	Director	-	-
9	Investment Corporation of Bangladesh Represented by Md. Golam Rabbani	Director	-	-
10	S.M. Harun Or Rashid	Independent Director	-	-
11	Md. Moniruj jaman	Independent Director	-	-
12	Md. Firoz Khan	Independent Director	Sabila Sea Foods Ltd.	Director

ELECTION OF DIRECTORS

Mrs. HafizaYeasmin, Mr. Md. Amin Ur Rashid and Md. Mizanur Rahman retires as per Article-55, 56, 57 of the Articles of Association of the company, being eligible, Mrs. HafizaYeasmin& Md. Mizanur Rahman have offered themselves for re-election. But Mr. Md. Amin Ur Rashid has desired to resign from Directorship of the Company. Brief resume and other information of the above mentioned directors are depicted in Annexure-II

DIRECTOR'S REMUNERATION

Director's remuneration is shown in the note no. 32 (a) of the notes to the Financial Statements. There is no remuneration for Independent Directors.

REMUNERATION

Name	Designation	Nature of Transaction	Amount in (BDT)	
			2018-2019	2017-2018
Mr. A.F.M Anowarul Huq	Managing Director	Remuneration	1,800,000	1,800,000

INDEPENDENT DIRECTORS:

In the terms of provision under the Corporate Governance Code dated: on 3 June 2018 the Board of Directors has appointed Mr. S M Harun Or Rashid, Mr. Md. Monirujjaman and Mr. Md. Firoz Khan as Independent Director of the Company for the period of three years which approved by Shareholders in AGM.

APPOINTMENT OF AUDITORS

The existing Auditors of the company **M/s Mahfel Huq & Co.**, Chartered Accountants, will retire at the conclusion of the Annual General Meeting. as per the requirement of Bangladesh Securities and Exchange Commission (BSEC) Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June, 2018, every public listed company shall not appoint any firm of Chartered Accounts as its statutory Auditors for a consecutive period exceeding the three years. Since M/s Mahfel Huq & Co. is eligible for reappointment, they have expressed their interest to perform the audit of the Company's financial statement for the year 2019-2020. Therefore, the Board of Directors proposed, Mahfel Huq & Co. Chartered Accounts to engage as Statutory Auditors subject to approval at the 5th Annual General Meeting to be held on December 12 by the members of the company upto the 6th Annual General Meeting to be held 2020.

PROFESSIONALS FOR COMPLIANCE OF CORPORATE GOVERNANCE CODE.

as per the requirement of Bangladesh Securities and Exchange Commission (BSEC) Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June, 2018, the Company shall obtain a certificate from a practicing Professional Accountant or Secretary other than its Statutory Auditors or Audit firm on yearly basis. Since, Shafiq Basak & Co. Chartered Accountants eligible for appoint, they have expressed their interest to perform Compliance Audit of the company. Therefore, the Board of Directors proposed, Suraiya Parveen & Associates Chartered Secretaries firm to engage subject to approval at the 5th Annual General Meeting to be held on December 12 by the members of the company.

RE-APPOINTMENT OF MANAGING DIRECTOR.

The tenure of the Managing Director, Mr. A F M Anowarul Huq has already been expired on 18th June, 2019. The Board of Directors in its meeting held on 9th May 2019 decided to re-appoint him for a further term of five years with effect from 19th June, 2019 for which they recommended for approval by the shareholders in the ensuing Annual General Meeting. Brief resume and other information of the Managing Director is depicted in Annexure-II.

RE-APPOINTMENT OF INDEPENDENT DIRECTOR

The Board of Directors in its meeting held on 27th June, 2019 decided to re-appoint Mr. S. M. Harun Or Rashid & Mr. Md. Monirujjaman as Independent Director of the Company for a further period of 3 (three) years with effect from 29th July, 2019 as per BSEC Regulations and recommended for approval by the shareholders in the ensuing Annual General Meeting. Brief resume and other information of the above mentioned independent director is depicted in ANNEXURE-II.

COMPANY SECRETARY, CHIEF FINANCIAL OFFICER, HEAD OF INTERNAL AUDIT

As per corporate governance code of BSEC, the company has allocated the responsibilities of the officials as follows:

Company Secretary	: Mohi Uddin QCS
Chief Financial Officer	: Md. Faruque Hossain
Head of Internal Audit	: Md. Abu Taleb

AUDIT COMMITTEE-

The Board has formed an Audit Committee of the Board consisting of three (3) member to assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and ensuring a good monitoring system within the business.

The Audit Committee carries out its responsibilities as per the provisions of law and submits its report to the Board of Directors from time to time. The Audit Committee shall also co-ordinate with the Internal and external Auditors as and when required. The Audit Committee ensures that adequate internal checks & balances supported by adequate MIS are in place for detection of errors frauds and other deficiencies. The other responsibilities include inter alia, not being limited to, the prevention of conflict of interest between the company and its Directors, officials, customers, suppliers, government and any other interest groups and detect or remove any scope of insider trading in the company's stock. The Audit Committee also ensures compliance of requirements of BSEC and other regulatory.

MEMBERS OF AUDIT COMMITTEE

The Board has established a committee of the Board known as the Audit Committee consisting of three (3) members to assist the Board

Chairman	S. M. Harun or Rashid
Members	Md. Amin-Ur-Rashid
	Fatima Parvin
In attendance	
Secretary	Mohi Uddin QCS, Company Secretary

Report of the Audit Committee is depicted Annexure -iv

NOMINATION & REMUNERATION COMMITTEE

The Board has formed a Nomination & Remuneration Committee of the Board consisting of three (3) members to assist the Board in formulation measures policy for determining qualifications, positive attributes, experiences and independence of director and top level executives.

The Nomination and Remuneration Committee shall assist the Board in formulation of the nomination criteria for a policy for formal process of considering remuneration of directors and top level executives

MEMBERS OF NOMINATION & REMUNERATION COMMITTEE

The Board has established a committee of the Board known as the Nomination & Remuneration Committee

CONSISTING OF THREE (3) MEMBERS TO ASSIST THE BOARD

Chairman	-Md. Monirujjaman.
Members	-Mrs. Sayeda Huq.
	-Md. Mizanur Rahman
In attendance	-Chairman -Managing Director -External Advisers – by invitation -Any Non-Executive Director shall be entitled to attend the Committee's meetings.
Secretary	-Mohi Uddin QCS, Company Secretary

Mr. Mohi Uddin, QCS Company Secretary is the Secretary to the nomination & Remuneration Committee. The number of the meeting held during year ended June 30, 2019 were 1(one).

MAINTAINING A WEBSITE

The company has been maintaining an official website www.indo-banglapharma.com which is linked with the website of the stock exchange.

SUBSIDIARY COMPANY

The company has no subsidiary company.

CORPORATE GOVERNANCE

Corporate Governance is the practice of good citizenship, through which the Company is governed by the Board, keeping in view its accountability to the stakeholders and to the society. In accordance with the requirement of Bangladesh Securities and Exchange Commission (BSEC) Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June, 2018, a statement in pursuance to Clause 1 (5), resume of the Directors who shall be appointed, Audit Committee Report as per clause 5 (7), Certificate from the CEO & CFO to the Board, Certificate on Compliance of Condition of Corporate Governance Code & Status of Compliance in depicted in the Annexure-I, II, III, IV, V A, B & C respectively.

GOING CONCERN

While approving the financial statements, the directors have made appropriate inquiries and analyzed the significant financial, operating as well as other indicators for enabling them to understand the ability of the Company to continue its operation for a conceivable period. Directors are confident and have a reasonable expectation that the Company has adequate resources to continue its operation consistently for the predictable future. Therefore, the company adopted the going concern basis in preparing the financial statement.

MANAGEMENT GRATITUDE

Finally, on behalf of the Board, I would like to take this opportunity to thank all the employees of Indo-Bangla Pharmaceuticals Ltd for their tremendous efforts. I would also like to express sincere gratitude to the shareholders as well as all Stakeholders of the company for their continued support.

The Board is also grateful to the Officers, Staff, Workers, Customers, Creditors, Banks, Insurance Companies, Utility Providers, BSEC, DSE, CSE, CDBL and the Government of Bangladesh and other business partner for their cooperation extended to the Company during the year.

Thanking you.

On behalf of the Board of Directors

Sd/-

(Aziza Yeasmin)

Chairman

STATEMENT OF DIRECTORS ON FINANCIAL REPORTS

In accordance with the Bangladesh Securities and Exchange Commission Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 03 June, 2018 The Directors also report that:

- a) The financial statements together with notes thereon have been drawn up in conformity with the Companies Act, 1994 and The Securities and Exchange Rules 1987. The Financial Statement of the Company present true and fair view of the Company's state of affairs, result of its operations, cash flows and changes in equity.
- b) Proper books of accounts of the company as required prevailing Law have been maintained.
- c) Appropriate accounting policies have been applied consistently in preparation of the financial statements and the accounting estimates are based on reasonable and prudent judgment.
- d) The Financial Statement was prepared in accordance with International Accounting Standards (IAS)/ International Financial Reporting Standards (IFRS)/Bangladesh Accounting Standard (BAS)
- e) Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress.
- f) There is no significant doubt about the Company's ability to continue as a going concern.
- g) There is no significant deviation from the last year's operating result of the Company.
- h) The system of internal control is sound and has been implemented and monitored effectively.
- i) The key operating and financial data for the last five years. (Page 31)

Board Meeting and Attendance

The number of Board meeting and the Attendance of Directors during the year 2018-2019 were as follows:

Name of the Directors	Position	Meeting held	Attended
Mrs. Aziza Yeasmin	Chairman	11	10
Mr. A.F.M Anowarul Huq	Managing Director	11	11
Mrs. HafizaYeasmin	Director	11	4
Md. Amin-Ur-Rashid	Director	11	10
Sayeda Huq	Director	11	10
Fatima Parvin	Director	11	11
Mst.Shanaj Akter	Director	11	8
Mizanur Rahman	Director	11	10
Investment Corporation of Bangladesh (ICB) represented by Md. Golam Rabbani	Director	11	4
S.M. Harun Or Rashid	Independent Director	11	10
Md. Monirujjaman	Independent Director	11	9
Md. Firoz Khan	Independent Director	11	8

DIRECTORS PROFILE.....

Who are seeking re-appointment

RE-APPOINTMENT OF MANAGING DIRECTOR



Mr. A F M Anowarul Huq.

Mr. AFM Anowarul Huq, is a Director of the Company since 2014 and has been appointed as Managing Director in 2014. He is the son of late Azizul Huq, founder of Indo-Bangla Pharmaceuticals Works. He obtained Master's Degree in Applied Chemistry, LLB degree from the National University and obtained certificate of completion on GMP Training in Various Countries by WHO. Having a prosperous experience of more than 21 years in Pharmaceuticals, Shipping, Apparels as well as others family Business.

Mr. Huq also a Sponsor Director in other private limited company namely HBS Apparels Limited., Talukder Dairy Firm Limited., IBP Agrovet Ltd., Sabila Sea Foods Ltd., BD Pharma Ltd.,

Mr. Huq was a Former President of Rotary club of Barisal Mid Town; Apex club of Barisal; Chairman of Employers Committee UCEP, Barisal; Director of the Barisal Chamber of Commerce & Industry; Director of FBCCI;

At present he is the member of Ghatail Golf Club (GGC), Bangladesh Association of Publicly Listed Companies (BAPLC), Bangladesh Association of Pharmaceuticals Industries (BAPI), Bangladesh Aushad Shilpa Samity; lifetime member of Barisal Club Ltd, Barisal; Diabetic Hospital, Barisal; Red Crescent, Barisal; Heart Foundation, Barisal; Anjuman-E Hemayat-E Islam, Barisal.

RE-APPOINTMENTS OF DIRECTORS

Mrs. Hafiza Yeasmin



Mrs. Hafiza Yeasmin is a Sponsor Director of Indo-Bangla Pharmaceuticals Ltd. since 2014. She is a daughter of late Azizul Huq, Founder of Indo-Bangla Pharmaceuticals Works. She completed MBA and PHD on Rural People Development from University of Copenhagen (Denmark) dated August 06, 2011 and has a business experiences of more than 12 years in the pharmaceuticals sector. After coming back from Denmark, she joined in Indo-Bangla Pharmaceuticals Ltd. as a Director and also director in other Private Limited Company.

Md. Mizanur Rahman

Md. Mizanur Rahman, is a Director of Indo-bangla Pharmaceuticals Ltd. since 2014 was born in 5 October, 1980 in Barisal, son of Md. Jalal Hawladar & Mrs. Minara Begum. He graduated from National University and has a business experiences of more than 10 years in the manufacturing industry including Pharmaceuticals sector. He is also Director in other Private Limited Company.

RE-APPOINTMENT OF INDEPENDENT DIRECTORS**Mr. S.M. Harun Or Rashid.**

Mr. Harun Or Rashid obtained B.Com. (Hons) from Dhaka University. Mr. S.M. Harun Or Rashid one of the former (retired) Govt. employee Having a prosperous experience of more than 15 years in Pharmaceuticals. He also involved with pharmaceuticals industry last 13 years.

Mr. Md. Monirujjaman


Mr. Md. Monirujjaman Advocate Hon'ble High Court son of AbdurRab Khan. He obtained Master of law from Dhaka International University & started Advocate practicing at the High Court Division of Bangladesh Supreme Court as well as involved in business. He has 13 years of business experience. He is an Independent Director of Indo-Bangla Pharmaceuticals Ltd.

Annexure – III

Pattern of Shareholding as on June 30, 2019

SHAREHOLDING PATTERN.

	Name of the Shareholders	Status	Share held	%
i.	Parent/Subsidiary /Associated Companies and other related parties	-	-	-
ii.	Directors:			
	Aziza Yeasmin	Chairman	2,205,500	2.16%
	A F M Anowarul Huq	Managing Director	13,678,500	13.37%
	Hafiza Yeasmin	Director	2,205,500	2.16%
	Md. Amin -Ur-Rashid	Director	2,766,500	2.70%
	Fatima Parvin	Director	2,707,100	2.65%
	Sayeda Huq	Director	2,201,100	2.15%
	Mst. Shahnaj Akter	Director	2,256,100	2.21%
	Mizanur Rahman	Director	2,256,100	2.21%
	Investment Corporation of Bangladesh Represent by			
	Md. Golam Rabbani	Director	16,500,000	16.13%
	S M Harun Or Rashid	Independent Director	-	-
	Md. Monijujjaman	Independent Director	-	-
	Md. Firoz Khan	Independent Director	-	-
iii.	Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children;			
	A F M Anowarul Huq	Chief Executive Officer	13,678,500	13.37%
	Md. Faruque Hossain	Chief Financial Officer	-	-
	Mohi Uddin QCS	Company Secretary	-	-
	Md. Abu Taleb	Head of Internal Audit	-	-
iv.	Executives:			
	Md. Anwar Hossain	AGM	-	-
	Shah-E-Azam	Plant Manager	-	-
	Mizanur Rahman	Head of Admin.	-	-
V.	Shareholders holding 10% or more voting interest in the company			



Pattern of Shareholding as on June 30, 2019

AUDIT COMMITTEE REPORT.

for the year 2018-2019

Indo-Bangla Pharmaceuticals Ltd. having an Audit Committee as a sub-committee of the Board of Directors in order to assist the Board of Directors in ensuring and fulfilling its oversight responsibilities.

THE AUDIT COMMITTEE CONSISTS OF THE FOLLOWING PERSONS:

S. M. Harun or Rashid, Independent Director	- Chairman
Mr. Md. Amin-Ur-Rashid, Director	- Member
Mrs. Fatima Parvin, Director	- Member
Mr. Mohi Uddin, Company Secretary	Secretary

THE SCOPE OF AUDIT COMMITTEE WAS DEFINED AS UNDER:

- (i) Review and recommend to the Board to approve the quarterly and annual financial statements prepared for statutory purpose;
- (ii) Monitor and oversee choice of accounting policies and principles, internal audit and Compliance process, management process, auditing manner, hiring and performance of external auditors;
- (iii) Review statement of significant related party transactions submitted by the management.
- (iv) Carry on a supervision role to safeguard the systems of governance and independence of statutory auditors and
- (v) Review and consider the report of internal auditors and statutory auditors' observations on internal control.

THE AUDIT COMMITTEE OF INDO-BANGLA PHARMACEUTICALS LTD. IS PLEASED TO CONFIRM THAT THE FOLLOWING ACTIVITIES HAVE BEEN CARRIED OUT DURING THE YEAR:

- Enhance good practices in financial reporting and risk management.
- Ensure establishment of adequate internal controls and compliance with laws and regulations.
- Ensure that the preparation, presentation and submission of financial statements have been made in accordance with the prevailing laws, standards and regulations.

In pursuance with Corporate Governance Code, 2018, the Audit Committee also reviewed the internal audit reports, the interim and annual financial statements and the financial performance of Indo-Bangla Pharmaceuticals Ltd. for the year ended June 30, 2019.

The Committee found adequate arrangement to present a true and fair view of the financial status of the company and did not find any material deviation, discrepancies or any adverse finding/observation in the areas of reporting.

Sd/-
S. M. Harun or Rashid
Chairman
Audit Committee

Date: 09 October, 2019

NOMINATION AND REMUNERATION COMMITTEE REPORT

The Board of Directors of Indo-Bangla Pharmaceuticals Ltd. has duly constituted a Nomination and Remuneration Committee (NRC), as per the requirement of the Corporate Governance Code of Bangladesh securities and Exchange Commission (BSEC) to shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executives as well as a policy for formal process of considering remuneration of directors, top level executives.

The statement of Nomination and Remuneration Committee is prepared as per Corporate Governance Code issued by BSEC.

COMPOSITION AND MEETINGS

The NRC of Indo-Bangla Pharmaceuticals Ltd. comprises of three (3) members who will exclusively be Non-Executive Directors, including one (1) Independent Director. The Committee includes:

1. Mr. Md. Moniruj jaman -Chairman
2. Mrs. SayedaHuq -Member
3. Mr. Md. Mizanur Rahman -Member

The Independent Director, Mr. Md. Monirujjaman acts as Chairman of the Committee. As per regulatory guidelines, the Company Secretary, Mr. mohi Uddin, QCS acts as Secretary to the Committee. The NRC, accordingly, performs in coherence and ensures compliance with the Corporate Governance Code promulgated by the Bangladesh Securities and Exchange Commission (BSEC).

Permanent invitees to the meetings are the Managing Director (MD), Any Non-Executive Director shall be entitled to attend the Committee's meetings and the Company Secretary. Relevant heads of divisions and other members of the Management team will also attend the meetings at occasions, as required.

RESPONSIBILITIES OF NRC

The purpose, authority, composition, duties and responsibilities of the Nomination and Remuneration Committee are delineated in its Charter. Some of the major responsibilities of the NRC are as follows:

- Recommend a policy to the Board relating to the remuneration of the Directors, and top level executives;
- Recommend a policy on Board's diversity taking into consideration age, gender, experience, education and nationality;
- Formulate the criteria for determining qualification and independence of Directors;
- Identify persons who are qualified to become Directors and in top level executives and recommend their appointment and removal;
- Formulate the criteria for evaluation of performance of Independent Directors;
- Assess that the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable Directors to run the company successfully;
- Evaluate that remuneration to Directors and top level executives involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;
- Identify the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;
- Recommend and review annually the Company's human resources and training policies;

- Recommend the remuneration policy of the Company, particularly in relation to the yearly increment principle; and
- Recommend the Code of Conduct for the Chair of the Board, other Board Members and Chief Executive Officer of the Company.

NOMINATION, RECRUITMENT AND SELECTION STANDARDS

Recruitment and selection processes for Board members identify candidates with the most suitable skills, knowledge, experiences and personal values. The NRC is responsible to ensure that the procedures for appointing new Directors are transparent and rigorous. The Board places great emphasis on ensuring its membership reflecting diversity in broader sense. A combination of age, gender, experience, ethnicity, educational background, nationality and other relevant personal attributes in the Board is important in providing a range of perspectives, insights and challenges needed to support right decision making.

EVALUATION CRITERIA

The evaluation process is led by the Chairman of the Board and assisted by the Company Secretary. The respective line authority of the Directors, Top level Executives sets the performance measurement criteria based on the respective role profile and responsibilities through the annual appraisal process. The NRC is responsible for ensuring the effectiveness of the Board. The Board shall carry out an evaluation once a year of its work, functions, performance as well as monitoring of internal control over financial reporting for the preparation of external financial statements and the safeguarding of assets. Each Director is required to complete a confidential pre-set questionnaire. The evaluation includes a review of the administration of the Board and its committees covering their operations, agenda, reports, and information produced for consideration, and relationship with Management.

SELECTION & REMUNERATION CRITERIA OF TOP LEVEL EXECUTIVE

The performance of the Company depends upon the quality of its Directors and Top Level Executives. To prosper, the Company must attract, motivate and retain highly skilled Directors and Executives. The recruitment process for Top Level Executives shall be transparent, non-discriminatory, diversified and in alignment with the Codes of Conduct.

REMUNERATION FOR BOARD OF DIRECTORS

Each Director shall receive reasonable remuneration from the Company for every meeting attended, plus travelling expenses from and to usual place of residence and an allowance per day for the number of days spent attending, travelling to and returning from Board meetings. The amounts will be determined by the Shareholders at the General Meeting.

ACTIVITIES OF THE NRC DURING THE REPORTING PERIOD

The activities of the NRC during the year were as follows:

- Consider the Terms of Reference (ToR) of NRC as approved by the Board of Directors;
- Formulate the policy relating to the remuneration of the Directors and top-level executives;
- Formulate the criteria for determining qualifications, positive attributes and independence of the Directors;
- Adopt Code of Conduct for the Chairman, Directors and Top-level Executive as per BSEC Notification;
- Criteria for evaluation of performance of Independent Directors;

For and on behalf of the Nomination and Remuneration Committee of Indo-Bangla Pharmaceuticals Ltd.

-Sd-

Mr. Md. Monirujjaman, Advocate.

Chairman,
13 October 2019

INDO-BANGLA PHARMACEUTICALS LTD. DECLARATION BY CEO AND CFO

The Board of Directors
Indo-Bangla Pharmaceuticals Ltd.
Bashundhara R/A, Baridhara,
Dhaka-1229

Date: 17 October, 2019

Subject: Declaration on Financial Statements for the year ended on 30 June, 2019.

Dear Sirs,


Pursuant to the condition No. 1(5)(xxvi) imposed vide the Commission's Notification No. BSEC/ CMRRCD/2006 -158/207/Admin/80 Dated 3 June, 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

1. The Financial Statements of Indo-Bangla Pharmaceuticals Ltd. for the year ended on 30th June, 2019 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in the Bangladesh and any departure there from has been adequately disclosed;
2. The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
3. The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;
4. To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
5. Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and
6. The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

In this regard, we also certify that: -

- (i) We have reviewed the financial statements for the year ended on 30th June, 2019 and that to the best of our knowledge and belief:
 - (a) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - (b) these statements collectively present true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.
- (ii) There are, to the best of knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,



A F M Anowarul Huq
Managing Director



Md. Faruque Hossain
Chief Financial Officer

CERTIFICATE ON COMPLIANCE

with the condition No. 1(5)(XVII) of
Corporate Governance Code

Annexure –B

Certificate as per condition No. 1(5)(xxvii)



CHATTOGRAM OFFICE:
National House (1st Floor),
109, Agrabad Commercial Area,
Chattogram - 4100, Bangladesh.
Phone : 88-031-711561
Pho/Fax : 88-031-723680
Web : www.shafiqbasak.com
E-mail : basak_sbc@yahoo.com
basak@shafiqbasak.com

CHARTERED ACCOUNTANTS

Partners:

Md. Shafiqul Islam, FCA
Sampad Kumar Basak, FCA
Md. Enayet Ullah, FCA
Sarwar Mahmood, FCA
Sheikh Zahidul Islam, MBA, FCA

DHAKA OFFICE -(1):
Shatabdi Centre (6th & 4th Floor),
292, Inner Circular Road,
Fakirapool, Motijheel, Dhaka.
Phone : 88-02-7194870
Pho/Fax : 88-02-7192098
Web : www.shafiqbasak.com
E-mail : shafiq_basak@yahoo.com
shafiq@shafiqbasak.com

Ref. No. : SB/IBPL-297/2019

Report to the Shareholders of Indo-Bangla Pharmaceuticals Ltd. on compliance on the Corporate Governance Code

We have examined the compliance status to the Corporate Governance Code by **Indo-Bangla Pharmaceuticals Ltd.** for the year ended on 30 June 2019. This Code relates to the Notification No.BSEC/CMRRCD/2006-158/207/Admin/80, dated 3 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our Examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is a scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

- The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission;
- The company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;
- Proper books and records have been kept by the company as required under the Companies Act, 1994, the securities laws and other relevant laws;
- The governance of the company is highly satisfactory.

Place: Dhaka
Dated: 20 November, 2019




(Md. Enayet Ullah, FCA)
Partner
SHAFIQ BASAK & CO.
CHARTERED ACCOUNTANTS



DHAKA OFFICE -(2): House - 42 (1st Floor), Road - 01, Block - A, Niketan, Gulshan - 01, Dhaka.
Phone : 88-02-99859602-3, 01819-285196, E-mail:mahmoods.bd@gmail.com

Indo-Bangla Pharmaceuticals Ltd.

Status of Compliance with the Corporate Governance Guideline (CGC)

Status of compliance with the conditions imposed by the Commission's Notification No.SEC/CMRRCD/2006-158/207/Admin/80 dated 3 June 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969:

(Report under Condition No. 9)

Condition No.	Title	Complied	Not Complied	Remarks (IF ANY)
1	Board of Directors			
1(1)	Size of the Board of Directors			
	The total number of the board members of the company shall not be less than 5 (five) and more than 20 (twenty)	√		
1(2)	Independent Directors			
1(2)(a)	At least one fifth (1/5) of the total number of directors in the company's board shall be independent directors.	√		
1(2)(b)	<i>For the purpose of this clause 'independent director' means a director-</i>			
1(2)(b)(i)	Who either does not hold any share in the company or holds less than one percent (1%) shares of the total paid-up shares of the company;	√		
1(2)(b)(ii)	who is not a sponsor of the company or is not connected with the company's any sponsor or director or nominated director or shareholder of the company or any of its associates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid-up shares of the company on the basis of family relationship and his or her family members shall not hold above mentioned shares in the company;	√		
1(2)(b)(iii)	who has not been an executive of the company in immediately preceding 2 (two) financial years;	√		
1(2)(b)(iv)	who does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary or associated companies;	√		
1(2)(b)(v)	who is not a member or TREC (Trading Right Entitlement Certificate) holder, director or officer of any stock exchange;	√		
1(2)(b)(vi)	who is not a shareholder, director excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	√		
1(2)(b)(vii)	who is not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the concerned company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance of this Code;	√		
1(2)(b)(viii)	who is not independent director in more than 5 (five) listed companies;	√		

1(2)(b)(ix)	who has not been convicted by a court of competent jurisdiction as a defaulter in payment of any loan or any advance to a bank or a Non-Bank Financial Institution (NBFi);	√		
1(2)(b)(x)	who has not been convicted for a criminal offence involving moral turpitude;	√		
1(2)(c)	The independent director(s) shall be appointed by the Board and approved by the shareholders in the Annual General Meeting (AGM);	√		
1(2)(d)	The post of independent director(s) cannot remain vacant for more than 90 (ninety) days;	√		
1(2)(e)	The tenure of office of an independent director shall be for a period of 3 (three) years, which may be extended for 1 (one) tenure only.	√		
1(3)	Qualification of Independent Director			
1(3)(a)	Independent Director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial laws, regulatory requirements and corporate laws and can make meaningful contribution to business;	√		
1(3)(b)	Independent Director shall have following qualifications			
1(3)(b)(i)	Business leader who is or was a promoter or director of an unlisted company having minimum paid up capital of Tk. 100.00 million or any listed company or a member of any national or international chamber of commerce or business association; or	-	-	N/A
1(3)(b)(ii)	Corporate leader who is or was a top level executive not lower than Chief Executive Officer or Managing Director or Deputy Managing Director or Chief Financial Officer or Head of Finance or Accounts or Company Secretary or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid up capital of Tk. 100.00 million or of a listed company;	√	-	
1(3)(b)(iii)	Former official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, who has at least educational background of bachelor degree in economics or commerce or business or law;			N/A
1(3)(b)(iv)	University Teacher who has educational background in Economics or Commerce or Business Studies or Law;	-	-	N/A
1(3)(b)(v)	Professional who is or was an advocate practicing at least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification;	-	-	N/A
1(3)(c)	The independent director shall have at least 10 (ten) years of experiences in any field mentioned in clause (b);	√		

1(3)(d)	In special cases, the above qualifications or experiences may be relaxed subject to prior approval of the Commission;			No such issue arose
1(4)	Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer			
1(4)(a)	The positions of the Chairperson of the Board and the Managing Director and/ or Chief Executive Officer (CEO) of the company shall be filled by different individuals;	√		
1(4)(b)	The Managing Director (MD) and/ or Chief Executive Officer (CEO) of a listed company shall not hold the same position in another listed company;	√		
1(4)(c)	The Chairperson of the Board shall be elected from among the non-executive directors of the company;	√		
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the chairperson and the Managing Director and/ or Chief Executive Officer;	√		
1(4)(e)	In the absence of the chairperson of the Board, the remaining members may elect one of themselves from non-executive directors as Chairperson for that particular Board's meeting; the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	√		
1(5)	The Directors' Report to Shareholders:			
	The Board of the company shall include the following additional statements or disclosures in the Directors' Report prepared under section 184 of the companies Act, 1994 (Act No. XVIII of 1994):-			
1(5)(i)	An industry outlook and possible future developments in the industry;	√		
1(5)(ii)	The Segment-wise or product-wise performance;	√		
1(5)(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	√		
1(5)(iv)	A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable;	√		
1(5)(v)	A discussion on continuity of any Extra-Ordinary activities and their implications (gain or loss);			No such issue arose
1(5)(vi)	A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions;	√		
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments;	√		
1(5)(viii)	An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Rights Share Offer, Direct Listing, etc;			No such issue arose
1(5)(ix)	An explanation on any significant variance that occurs between Quarterly Financial performance and Annual Financial statements;			No such matter to explain
1(5)(x)	A statement of remuneration paid to the directors including independent directors	√		

1(5)(xi)	The financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	√		
1(5)(xii)	Proper books of account of the issuer company have been maintained;	√		
1(5)(xiii)	Appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	√		
1(5)(xiv)	International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there from has been adequately disclosed;	√		
1(5)(xv)	The system of internal control is sound in design and has been effectively implemented and monitored;	√		
1(5)(xvi)	Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	√		
1(5)(xvii)	There is no significant doubt upon the issuer company's ability to continue as a going concern, if the issuer company is not considered to be a going concern, the fact along with reasons there of shall be disclosed;	√		
1(5)(xviii)	An explanation that significant deviations from the last year's operating results of the issuer company shall be highlighted and the reasons thereof shall be explained;			No such matter to explain
1(5)(xix)	Key operating and financial data of at least preceding 5 (five) years shall be summarized;	√		
1(5)(xx)	An explanation on the reasons if the issuer company has not declared dividend (cash or stock) for the year;			The BOD declared dividend
1(5)(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;			N/A
1(5)(xxii)	The total number of Board meetings held during the year and attendance by each director;	√		
1(5)(xxiii)	A report on the pattern of shareholding disclosing the aggregate number of shares (along with name-wise details where stated below) held by:-			
1(5)(xxiii)(a)	Parent or Subsidiary or Associated Companies and other related parties (name-wise details);	√		
1(5)(xxiii)(b)	Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children (name-wise details);	√		
1(5)(xxiii)(c)	Executives; and	√		
1(5)(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details);	√		
1(5)(xxiv)	In case of the appointment or reappointment of a director, a disclosure on the following information to the shareholders:-			
1(5)(xxiv)(a)	a brief resume of the director	√		

1(5)(xxiv)(b)	nature of his or her expertise in specific functional areas;	√		
1(5)(xxiv)(c)	names of companies in which the person also holds the directorship and the membership of committees of the Board;	√		
1(5)(xxv)	Management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with a brief discussion of changes in the financial statements, among others, focusing on:	√		
1(5)(xxv)(a)	accounting policies and estimation for preparation of financial statements;	√		
1(5)(xxv)(b)	changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;	√		
1(5)(xxv)(c)	comparative analysis (including effects of inflation) of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;	√		
1(5)(xxv)(d)	compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	√		
1(5)(xxv)(e)	briefly explain the financial and economic scenario of the country and the globe;	√		
1(5)(xxv)(f)	risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company;	√		
1(5)(xxv)(g)	future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM;	√		
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure-A;	√		
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9 shall be disclosed as per Annexure-B and Annexure-C.	√		
1(6)	Meetings of the Board of Directors:			
	The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Code.	√		
1(7)	Code of Conduct for the Chairperson, other Board members and Chief Executive Officer			

1(7)(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC) at condition No. 6, for the Chairperson of the Board, other board members and Chief Executive Officer of the company;	√		
1(7)(b)	The code of conduct as determined by the NRC shall be posted on the website of the company including, among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.	√		
2	Governance of Board of Directors of Subsidiary Company			
2(a)	Provisions relating to the composition of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary company;	-	-	N/A
2(b)	At least 1 (one) independent director on the Board of the holding company shall be a director on the Board of the subsidiary company;	-	-	N/A
2(c)	The minutes of the Board meeting of the subsidiary company shall be placed for review at the following Board meeting of the holding company;	-	-	N/A
2(d)	The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also;	-	-	N/A
2(e)	The Audit Committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company.	-	-	N/A
3	Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS)			
3(1)	Appointment			
3(1)(a)	The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC);	√		
3(1)(b)	The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and Head of Internal Audit and Compliance (HIAC) shall be filled by different individuals;	√		
3(1)(c)	The MD or CEO, CS, CFO and HIAC of a listed company shall not hold any executive position in any other company at the same time;	√		
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	√		
3(1)(e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s).	√		
3(2)	Requirement to attend Board of Directors' Meetings:			

	The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board provided that CS, CFO and HIAC shall not attend such part of a meetings of the Board relating to their personal matter.	√		
3(3)	Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO)			
3(3)(a)	The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year and that to the best of their knowledge and belief:	√		
3(3)(a)(i)	these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading; and	√		
3(3)(a)(ii)	these statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	√		
3(3)(b)	The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board or its members	√		
3(3)(c)	The certification of the MD or CEO and CFO shall be disclosed in the Annual Report.	√		
4	Board of Directors' Committee:- For ensuring good governance in the company, the Board shall have at least following subcommittees:			
4(i)	Audit Committee	√		
4(ii)	Nomination and Remuneration Committee	√		
5	Audit Committee			
5(1)	Responsibility to the Board of Directors			
5(1)(a)	The company shall have an Audit Committee as a sub-committee of the Board;	√		
5(1)(b)	The Audit Committee shall assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business;	√		
5(1)(c)	The Audit Committee shall be responsible to the Board; the duties of the Audit Committee shall be clearly set forth in writing.	√		
5(2)	Constitution of the Audit Committee			
5(2)(a)	The Audit Committee shall be composed of at least 3 (three) members;	√		
5(2)(b)	The Board shall appoint members of the Audit Committee who shall be non-executive directors of the company excepting Chairperson of the Board and shall include at least 1 (one) independent director;	√		
5(2)(c)	All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience;	√		

5(2)(d)	When the term of service of any Committee member expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 1 (one) month from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;	√		
5(2)(e)	The company secretary shall act as the secretary of the Committee;	√		
5(2)(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director.	√		
5(3)	Chairperson of the Audit Committee			
5(3)(a)	The Board shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an independent director;	√		
5(3)(b)	In the absence of the Chairperson of the Audit Committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No. 5(4)(b) and the reason of absence of the regular Chairperson shall be duly recorded in the minutes.			No such Incident arose
5(3)(c)	Chairperson of the Audit Committee shall remain present in the Annual General Meeting (AGM);	√		
5(4)	Meeting of the Audit Committee			
5(4)(a)	The Audit Committee shall conduct at least its four meetings in a financial year	√		
5(4)(b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	√		
5(5)	Role of Audit Committee: The Audit Committee shall:-			
5(5)(a)	Oversee the financial reporting process;	√		
5(5)(b)	monitor choice of accounting policies and principles;	√		
5(5)(c)	monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;	√		
5(5)(d)	oversee hiring and performance of external auditors;	√		
5(5)(e)	hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;	√		
5(5)(f)	review along with the management, the annual financial statements before submission to the Board for approval;	√		
5(5)(g)	review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;	√		
5(5)(h)	review the adequacy of internal audit function;	√		
5(5)(i)	review the Management's Discussion and Analysis before disclosing in the Annual Report;	√		

5(5)(j)	review statement of all related party transactions submitted by the management;	√		
5(5)(k)	review Management Letters or Letter of Internal Control weakness issued by statutory auditors;	√		
5(5)(l)	oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors;	√		
5(5)(m)	oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission;	√		
5(6)	Reporting of the Audit Committee			
5(6)(a)	Reporting to the Board of Directors			
5(6)(a)(i)	The Audit Committee shall report on its activities to the Board.	√		
5(6)(a)(ii)	The Audit Committee shall immediately report to the Board on the following findings, if any:-			
5(6)(a)(ii)(a)	report on conflicts of interests;			No such Incident arose
5(6)(a)(ii)(b)	suspected or presumed fraud or irregularity or material defect identified in the internal audit and compliance process or in the financial statements;			No such Incident arose
5(6)(a)(ii)(c)	suspected infringement of laws, regulatory compliances including securities related laws, rules and regulations;			No such Incident arose
5(6)(a)(ii)(d)	any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately;			No such Incident arose
5(6)(b)	Reporting to the Authorities:			
	If the Audit Committee has reported to the Board about anything which has material impact on the financial condition and results of operation and has discussed with the Board and the management that any rectification is necessary and if the Audit Committee finds that such rectification has been unreasonably ignored, the Audit Committee shall report such finding to the Commission, upon reporting of such matters to the Board for three times or completion of a period of 6 (six) months from the date of first reporting to the Board, whichever is earlier.			No such reportable incident arose
5(7)	Reporting to the Shareholders and General Investors:			
	Report on activities carried out by the Audit Committee, including any report made to the Board under condition No. 5(6)(a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer company.	√		Activities of Audit Committee are disclosed in the Annual Report.
6	Nomination and Remuneration Committee (NRC)			
6(1)	Responsibility to the Board of Directors			
6(1)(a)	The company shall have a Nomination and Remuneration Committee (NRC) as a subcommittee of the Board;	√		

6(1)(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive;	√		
6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b).	√		
6(2)	Constitution of the NRC			
6(2)(a)	The Committee shall comprise of at least three members including an independent director;	√		
6(2)(b)	All members of the Committee shall be non-executive directors;	√		
6(2)(c)	Members of the Committee shall be nominated and appointed by the Board;	√		
6(2)(d)	The Board shall have authority to remove and appoint any member of the Committee;	√		
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;			No such Incident arose
6(2)(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;			No such Incident arose
6(2)(g)	The company secretary shall act as the secretary of the Committee;	√		
6(2)(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an independent director;	√		
6(2)(i)	No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company.	√		
6(3)	Chairperson of the NRC			
6(3)(a)	The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	√		
6(3)(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;			No such Incident arose
6(3)(c)	The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders.	√		
6(4)	Meeting of the NRC			
6(4)(a)	The NRC shall conduct at least one meeting in a financial year;	√		
6(4)(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;	√		

6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	√		
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.	√		
6(5)	Role of the NRC			
6(5)(a)	NRC shall be independent and responsible or accountable to the Board and to the shareholders;	√		
6(5)(b)	NRC shall oversee, among others, the following matters and make report with recommendation to the Board;	√		
6(5)(b)(i)	formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following:	√		
6(5)(b)(i)(a)	the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully;	√		
6(5)(b)(i)(b)	the relationship of remuneration to performance is clear and meets appropriate performance benchmarks;	√		
6(5)(b)(i)(c)	remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;	√		
6(5)(b)(ii)	devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;	√		
6(5)(b)(iii)	identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;	√		
6(5)(b)(iv)	formulating the criteria for evaluation of performance of independent directors and the Board;	√		
6(5)(b)(v)	identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;	√		
6(5)(b)(vi)	developing, recommending and reviewing annually the company's human resources and training policies;	√		
6(5)(c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual Report.	√		
7	External or Statutory Auditors			
7(1)	The issuer company shall not engage its external or statutory auditors to perform the following services of the company, namely:-			
7(1)(i)	appraisal or valuation services or fairness opinions;	√		
7(1)(ii)	financial information systems design and implementation;	√		
7(1)(iii)	book-keeping or other services related to the accounting records or financial statements;	√		
7(1)(iv)	broker-dealer services;	√		
7(1)(v)	actuarial services;	√		

7(1)(vi)	internal audit services or special audit services;	√		
7(1)(vii)	any service that the Audit Committee determines;	√		
7(1)(viii)	audit or certification services on compliance of corporate governance as required under condition No. 9(1);	√		
7(1)(ix)	any other service that creates conflict of interest.			No such incident arose
7(2)	No partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company; his or her family members also shall not hold any shares in the said company	√		
7(3)	Representative of external or statutory auditors shall remain present in the Shareholders' Meeting (AGM or EGM) to answer the queries of the shareholders.	√		
8	Maintaining a website by the Company			
8(1)	The company shall have an official website linked with the website of the stock exchange.	√		
8(2)	The company shall keep the website functional from the date of listing.	√		
8(3)	The company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchange(s).	√		
9	Reporting and Compliance of Corporate Governance			
9(1)	The company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of conditions of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in the Annual Report.	√		
9(2)	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the shareholders in the annual general meeting.	√		
9(3)	The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions or not.	√		

Independent Auditor's Report To the Shareholders of Indo-Bangla Pharmaceuticals Ltd.

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Indo-Bangla Pharmaceuticals Ltd, which comprise the statement of financial position as at June 30, 2019, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at June 30, 2019, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs).

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

SL	Risk	Our response to the risk
1.	<p>Valuation of Inventories Refer to note 05 to the financial statements.</p> <p>Inventories represent about 12.79%, of the total assets of the Company amounting BDT 1,585.74 million; inventories are thus a material item to the Financial statements.</p> <p>As described in the accounting policy note 2.11 to the financial statements, inventories are valued at the lower of cost or net realizable values. As such, management is required to make judgments in determining whether inventories are being appropriately valued.</p> <p>Volume of inventories being held by the company at the reporting date and the complexities involved in the accounting and presentation thereof, Inventories has been considered as a key audit matter.</p>	<ul style="list-style-type: none"> • Tested the operating effectiveness of key controls over Inventories; including observing the process of management's Year-end inventory count. • Verified a sample of inventory items to ensure that costs have been appropriately recorded. • Tested on a sample basis the net realizable value by comparing costs to recent selling prices and assessing the reasonableness of any resulting write down of inventory items. • Performed cut-off tests to determine that the purchases and sales of the inventories have been captured in the correct accounting period. • Reviewed the historical accuracy of inventory provisions and the level of write-downs.

SL	Risk	Our response to the risk
2.	<p>Addition to Property, Plant and Equipment</p> <p>Refer to note 03 to the financial statements.</p> <p>The Company made significant addition to Property Plant & Equipment BDT 126.82 million. There is therefore a risk that the assets and depreciation charge may be misstated.</p>	<p>Our audit procedures included, among others, considering the risk of addition to Property, Plant and Equipment associated with the different types of asset:</p> <ul style="list-style-type: none"> • We critically assessed and verified the Company's policy of asset addition. • We assessed the appropriateness of the value of the assets. • We also recalculated the depreciation to assess the sensitivity of the key assumptions including depreciation rate.

Other Information

Management is responsible for the other information. The other information comprises the information including Director's report included in the annual report but does not include in the financial statements and our auditors' report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements

As part of an audit in accordance with ISAs, we exercise professional judgments and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Company's financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994 and the Securities and Exchange Rules 1987, we also report the following:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books;
- c) the statements of financial position and statements of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts and returns; and
- d) the expenditure incurred was for the purposes of the Company's business.

Place: Dhaka, Bangladesh

Dated: : 28 October, 2019



Md. Abu Kaiser FCA
Mahfel Huq & Co.
Chartered Accountants

INDO-BANGLA PHARMACEUTICALS LTD
STATEMENT OF FINANCIAL POSITION
As at 30 June, 2019

Particulars	Notes	Amounts in Taka	
		30-Jun-19	30-Jun-18
ASSETS:			
Non-current Assets		818,523,321	654,019,821
Property, Plant and Equipment	3.00	743,134,778	648,473,901
Capital Work In Progress	4.00	75,388,543	5,545,920
Current Assets		767,224,351	565,947,614
Inventories	5.00	202,867,111	166,752,790
Trade & Other Receivables	6.00	180,041,951	188,296,158
Advance, Deposits and Prepayments	7.00	223,733,862	119,219,047
Cash and Cash equivalents	8.00	160,581,427	91,679,619
TOTAL ASSETS		1,585,747,672	1,219,967,435
EQUITY AND LIABILITIES:			
Shareholders' Equity		1,374,627,332	1,036,100,643
Share Capital	9.00	1,023,000,000	730,000,000
Retained Earnings	10.00	351,627,332	306,100,643
Non-Current Liabilities		66,759,081	67,249,601
Deferred Tax Liability	11.00	66,759,081	67,249,601
Current Liabilities		144,361,259	116,617,191
Provision for WPPF	12.00	9,038,917	7,576,461
Trade Payables	13.00	6,108,271	6,541,572
Provision for Income Tax	14.00	123,615,998	97,573,822
Liabilities for Expenses	15.00	5,598,073	4,925,336
TOTAL OWNER'S EQUITY AND LIABILITIES		1,585,747,672	1,219,967,435
Net Asset Value (NAV) Per Share	23.00	13.44	14.19

Annexed notes form an integral part of these financial statements.


Chief Financial Officer


Company Secretary


Director


Managing Director

Signed in terms of our annexed report of even date.

Place: Dhaka
 Date: 28 October, 2019


Mahfel Huq & Co.
Chartered Accountants


INDO-BANGLA PHARMACEUTICALS LTD
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
For the year ended 30 June, 2019

Particulars	Notes	Amount in Taka	
		30-Jun-19	30-Jun-18
Net Sales Revenue	16.00	740,714,183	659,971,100
Less: Cost of Sales	17.00	444,163,230	399,570,368
Gross Profit		296,550,952	260,400,732
Less: Operating Expenses		118,269,079	107,222,621
Administrative Expenses	18.00	36,552,436	30,320,291
Selling & Distributing Expenses	19.00	81,716,643	76,902,330
Profit from Operations		178,281,873	153,178,111
Add: Non Operating Income	20.00	11,535,389	5,927,580
Profit before Contribution to WPPF & Welfare Fund		189,817,262	159,105,691
Less: Contribution to WPPF & Welfare Fund	12.00	9,038,917	7,576,461
Profit before Tax		180,778,345	151,529,230
Less: Income Tax Expenses		25,551,656	53,035,230
Current Tax	21.00	26,042,176	23,965,820
Deferred Tax	11.00	(490,520)	29,069,410
Net profit for the year		155,226,689	98,493,999
Earnings Per Share (EPS)	22.00	1.58	1.20

Annexed notes form an integral part of these financial statements.


Chief Financial Officer


Company Secretary


Director


Managing Director

Signed in terms of our annexed report of even date.

Place: Dhaka
 Date: 28 October, 2019


Mahfel Huq & Co.
Chartered Accountants

INDO-BANGLA PHARMACEUTICALS LTD
STATEMENT OF CHANGES IN EQUITY
For the year ended 30 June, 2019

Particulars	Share Capital	Retained Earnings	Total
Balance as on 01-07-2018	730,000,000	306,100,643	1,036,100,643
Issue of share Capital (IPO)	200,000,000	-	200,000,000
Issue of share Capital (Bonus)	93,000,000	(93,000,000)	-
IPO Expenses	-	(16,700,000)	(16,700,000)
Net Profit for the year	-	155,226,689	155,226,689
Balance as on 30-06-2019	1,023,000,000	351,627,332	1,374,627,332

INDO-BANGLA PHARMACEUTICALS LTD
STATEMENT OF CHANGES IN EQUITY
For the year ended 30 June, 2018

Particulars	Share Capital	Retained Earnings	Total
Balance as on 01-07-2017	730,000,000	207,606,643	937,606,643
Net Profit for the year	-	98,493,999	98,493,999
Balance as on 30-06-2018	730,000,000	306,100,643	1,036,100,643

Annexed notes form an integral part of these financial statements.


Chief Financial Officer


Company Secretary


Director


Managing Director


INDO-BANGLA PHARMACEUTICALS LTD
STATEMENT OF CASH FLOWS
For the year ended 30 June, 2019

Particulars	Notes	Amounts in Taka	
		30-Jun-19	30-Jun-18
(A) Cash Flow From Operating Activities :			
Cash receipts from customers	26.00	750,125,650	635,487,960
Cash receipts from others income	27.00	14,564,437	5,971,690
Cash payment to suppliers	28.00	(429,631,922)	(401,861,730)
Cash payment to employees		(63,290,278)	(60,827,019)
Cash payment to others		(79,684,302)	(70,469,121)
Cash generate from operation		192,083,585	108,301,780
Cash payment against income Tax		(25,294,755)	(20,848,700)
Net Cash From Operating Activities		166,788,830	87,453,080
(B) Cash Flow from Investing Activities :			
Acquisition of property, plant and equipment	29.00	(84,235,781)	(70,453,822)
Paid for Work In Progress	30.00	(69,842,623)	(5,545,920)
Paid for Land (Gazipur)		(100,000,000)	-
Advance paid for L/C Margin Machinery	31.00	(27,908,618)	(36,585,950)
Net Cash used in Investing Activities		(281,987,022)	(112,585,692)
(C) Cash Flow From Financing Activities :			
Proceeds from issue of share capital		200,000,000	-
IPO Expenses		(15,900,000)	-
Net Cash From Financing Activities		184,100,000	-
Net increase/decrease in cash & cash equivalents (A+B+C)		68,901,808	(25,132,612)
Cash & cash equivalents at beginning of the year		91,679,619	116,812,231
Cash and Cash Equivalent at end of the year		160,581,427	91,679,619
Net Operating Cash Flows Per Share (NOCFPS)	24.00	1.70	1.06

Annexed notes form an integral part of these financial statements.


Chief Financial Officer


Company Secretary


Director


Managing Director

INDO-BANGLA PHARMACEUTICALS LTD.
Notes to the Financial Statements and other explanatory information
As at and for the year ended June 30, 2019

1.00 REPORTING ENTITY

1.01 Background of the Company Indo-Bangla Pharmaceuticals Limited was

incorporated as a private Limited Company under the Companies Act-1994 on 18 June 2014 vide registration no.C-116665/14 through takeover of M/S. Indo-Bangla Pharmaceutical Works, a proprietorship business since pre-liberation period. The company has been converted into public limited company on 21-10-2014. Registered office of the company and Factory is at Aziz Bhaban, College Road, Barisal. Authorized capital of the company is Tk.1,500,000,000 divided into 150,000,000 ordinary shares of Tk.10 each. Paid up capital of the company is Tk.1,023,000,000 divided into 102,300,000 ordinary shares of Tk. 10 each.

1.02 Registered Office of the Company

The registered office of the Company and the Factory is located at 729, College Road, Barisal Sadar, Barisal and having its Corporate office at Polt-183 (7th floor) Block-B, Road-4, Ahmed Akbar Sobhan Road, Basundhara R/A, Baridhara, Dhaka-1229.

1.03 Nature of the business

The Company is engaged in manufacturing and selling of all kinds of medicine (excluding Antibiotic), medical preparations drugs & chemicals (Human Health) with due approval of Drug Administration Authority. The company applied for permission for production and selling of veterinary medicine also.

2.00 IAS IS OF PREPARATION AND PRESENTATION OF FINANCIAL STATEMENTS

2.01 Presentation of Financial Statements

The Financial Statements of the Company are prepared on a going concern IASs under historical cost convention and in accordance with the International Accounting Standards (IAS), International Financial Reporting Standards (IFRS), the Companies Act, 1994, the Securities and Exchange Rules, 1987 and other laws & regulation in Bangladesh applicable to the Company.

2.02 Going Concern

The company has adequate resources to continue its operation for the foreseeable future. The current credit facilities and resources of the company provides sufficient fund to meet the present requirements of its existing business. As such, the directors intended to adopt the going concern IASs in preparing the financial statements.

2.03 Accrual Basis

The financial statements have been prepared, except Statements of Cash Flows, using the accrual Basis of accounting.

2.04 Components of the Financial Statements

According to IFRS-1 “presentation of the Financial Statements” the complete set of financial statement includes the following components;

- a) Statement of Financial Position as at June 30, 2019;
- b) Statement of Profit or Loss and other Comprehensive Income for the period from 1st July 2018 to 30th June, 2019;
- c) Statement of Changes in Equity for the year ended June 30, 2019;
- d) Statement of Cash Flows for the year ended June 30, 2019; and
- e) Notes, summary of significant accounting policies and other explanatory information.

2.05 Accounting Policies & Estimates

The preparation of these financial statements is in conformity with IASs and IFRSs which require management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Estimates and underlying assumptions are reviewed on an ongoing IASs and used for accounting of certain terms such as provision for expenses and depreciation.

2.06 Responsibility for Preparation and Presentation of Financial Statements

The Board of Directors is responsible for the preparation of financial statements under section 183 of the Companies Act, 1994 and as per the provision of “the Framework for the preparation and Presentation of Financial Statements” issued by the International Accounting Standards (IAS) and Bangladesh Securities and Exchange Commission (BSEC) guideline.

2.07 Statement of Cash flows

Statement of Cash flows have been prepared in accordance with IAS-7 "Statement of Cash Flows" and the cash flows from the operating activities have been presented under direct method considering the provisions of Paragraph 19 of IAS-7 which provides that "Entities are encouraged to report cash flows from operating activities using the direct method".

2.08 Applicable accounting standards

The following IAS and IFRS are applicable for the financial statements for the year under review:

IASs:

- IAS -1 Presentation of Financial Statements
- IAS -2 Inventories
- IAS -7 Statements of Cash flows
- IAS -8 Accounting Policies, Changes in Accounting Estimates and Errors
- IAS-10 Events after the Reporting Period
- IAS-12 Income Taxes
- IAS-16 Property, Plant and Equipment
- IAS- 18 Revenue
- IAS -19 Employee Benefits
- IAS-24 Related Party Disclosures
- IAS- 32 Financial Instruments Presentation
- IAS-33 Earnings per Share
- IAS-36 Impairment of Assets
- IAS- 37 Provisions, Contingent Liabilities and Contingent Assets

IFRSs:

- IFRS 7 Financial Instruments: Disclosures
- IFRS 8 Operating Segments
- IFRS 9 Financial Instruments
- IFRS 15 Revenue from Contracts with Customers

2.09 Property, Plant and Equipment

2.09.1 Recognition and Measurement

All Property, Plant and Equipment are stated at cost less accumulated depreciation as per IAS-16 “Property, Plant and Equipment”. The cost of acquisition of an asset comprises of its purchase price and any directly attributable cost of bringing the asset to its working condition for its intended use inclusive of inward freight, duties and non- refundable taxes. The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its costs can be measured reliably.

The cost of the day to day maintaining cost on PPE is recognized in the Statements of Profit or Loss and other Comprehensive Income as incurred.

2.09.2 Depreciation

Depreciation on Property, Plant and Equipment other than Land has been computed during the year using the reducing balance method. Depreciation has been charged on addition when the related Property, Plant and Equipment are available for use as per management intention. Depreciation has been charged at following rates:

Name of Assets	Rate 2019	Rate 2018
Land and Land Development	0%	0%
Building	2.50%	2.50%
Machineries & Equipment	3%	3%
Micro biological Lab	3%	3%
Factory Air Condition	10%	10%
Generator	3%	3%
Furniture & Fixture	10%	10%
Office Equipment	10%	10%
SEP Decoration	10%	10%
Office Decoration	10%	10%
Computer	10%	10%
Air Condition	10%	10%
Transport	10%	10%
Water Plant	10%	10%
ETP Plant	10%	10%

2.09.3 Retirement and Disposals

An asset is derecognized on disposal or when no future economic benefits are expected from its use and subsequent disposal. Gain or loss arising from the retirement or disposal of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the assets and is recognized as gain or loss from disposal of asset under other income in the statement of profit or loss and other comprehensive income.

2.09.4 Impairment

All fixed assets have been reviewed and it was confirmed that no such fixed assets have been impaired during the period and for this reason no provision has been made for Impairment of assets as per IAS 36.

2.10 Revenue Recognition

As per IFRS-15: "Revenue from Contracts form Customers" the company accounts for a contract with a customer only when all of the following criteria are met:

- The parties to the contract have approved the contract (in writing, orally or in accordance with other customary business practices) and are committed to perform their respective obligations;
- The company can identify each party 's rights regarding the goods or services to be transferred ;
- The company can identify the payment terms for the goods or services to be transferred
- The contract has commercial substance (i.e. the risk , timing or amount of the entity `s future cash flows is expected to change as a result of the contract); and
- It is probable that the company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.

2.11 Valuation of Current Assets

Trade and Other Receivable

These are carried forward at their original invoiced value amount and represents net realizable value. Management considered the entire bills receivable as good and is collectable and therefore, no amount has been provided for as bad debt in the current year's account.

Inventories

In compliance with the requirements of IAS-2 “Inventories”, the inventories have been valued at Cost or Net Realizable value whichever is lower, which is consistent with the previous period’s practice. Net realizable value is based on estimated selling price in the ordinary course of business less any further cost expected to be incurred to make the sale.

2.12 Provisions:

A provision is recognized when

- a) the company has an obligation (legal or constructive) as a result of past events;
- b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and
- c) Reliable estimates can be made of the amount of the obligation.

2.13 Employees’ Benefit

The company maintains defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective deeds.

The company has accounted for and disclosed employee benefits in compliance with the provisions of IAS 19: “Employee Benefits”. The cost of employee benefit is charged off as revenue expenditure in the year to which the contributions relate.

The company’s employee benefits include the following.

a) Short Term Employee Benefit

Short-term employee benefits include wages, salaries, festival bonuses etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

b) Contribution to Workers’ Profit Participation and Welfare Funds

This represents 5% of net profit before tax but after charging such expenses by the company as per provisions of the Bangladesh Labor Act, 2006, & Bangladesh Labor (amendment) Act, 2013.

2.14 Advances, Deposits and Prepayments

Advances are initially measured at cost. After initial recognition advances are carried at cost less deductions, adjustments or charges to other account heads such as PPE or inventory etc.

2.15 Functional and Presentational Currency:

The financial statements are prepared in Bangladeshi Taka which is the Company’s functional currency.

2.16 Income Tax

Provision for taxation is calculated on the basis of applicable current tax rate in compliance with Finance Act, 2018. Any adjustment to tax payable in respect of previous years has been made.

Deferred Tax

The company recognized deferred tax as per IAS 12 “Income Taxes”. Deferred tax is recognized for all temporary timing difference arising between the carrying value of assets and liabilities and its tax base values during the year. The tax rate prevailing at the Financial Position date is used to determine the deferred tax.

2.17 Earnings per Share

The company calculates Earnings per Share (EPS) in accordance with IAS-33 “Earnings per Share” which has been shown on the face of the Profit or Loss and other Comprehensive Income.

Basic Earnings

This represents profit or loss at the end of the period attributable to ordinary shareholders of the entity.

Basic Earnings per Share

This has been calculated by dividing profit or loss attributable to ordinary shareholders of the entity by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share

Diluted EPS is determined by the adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there was no potential dilutive ordinary shares during the year ended 30 June 2019.

2.18 Financial Instruments

A financial instrument is any contract that gives rise to a financial asset to one entity and a financial liability or equity instrument to another entity as per IAS-39 “Financial Instruments Recognition and Measurement.”

Financial Assets

Financial assets of the company include cash and cash equivalents, Trade receivables and other receivables. The company initially recognizes a financial asset in its statement of financial position when, and only when, the company becomes a party to the contractual provision of the instrument. The company derecognizes a financial asset when, and only when; the contractual rights to the cash flows from the financial asset expire or transfer the contractual rights to receive the cash flows of the financial asset.

Financial Liabilities

Financial liabilities of the company include trade payables and liabilities for expenses. The company initially recognizes a financial liability in its statement of financial position when, and only when, the company becomes a party to the contractual provision of the instrument. The company derecognizes a financial liability from its statement of financial position when, and only when, it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires.

2.19 Cash and Cash Equivalents

According to IAS-7 ‘Statement of Cash Flows’, cash comprises cash in hand, short term deposit and highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in values.

2.20 Events after the Reporting Period

Events after the reporting period are those events, favorable and unfavorable, that occur between the end of the reporting period and the date when the financial statements are authorized for issue. Two types of events can be identified:

Adjusting Events are those that provide evidence of conditions that existed at the end of the reporting period. Non-adjusting Events are those that are indicative of conditions that arose after the reporting period.

2.21 Authorization date for issuing Financial Statements

The financial statements were authorized by the Board of Directors on October 28, 2019.

2.22 Comparative Information

Comparative information has been disclosed in the respect of previous year for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year’s financial statement.

2.23 Segmental Reporting

As required by IFRS-8 "Operating Segments", if an entity operates business activities that may earn revenues or incur expenses, whose operating results are regularly reviewed by the chief operating decision maker and for which discrete financial information is available

- a) that engages in business activities that may earn revenues or incur expenses;
- b) whose operating results are regularly reviewed by the entity’s chief operating decision maker to made a decisions about researches to be allocated to the segment and assess its performance; and
- c) for which discrete financial information is available

The company considers the operation on aggregate basis and manages the operations as a single operating segment. Hence it is felt that such segment reporting is not required to be disclosed.

2.24 Related Party Disclosure

The company carried out a number of transactions with related parties in the normal course of business and on arms' length basis. The information as required by IAS-24: Related Party Disclosures has been disclosed in a separate note to the financial statements.

2.25 General

- i) The figure has been rounded off to the nearest taka.
- ii) The financial Statements have been prepared covering one year from July 01, 2018 to June 30, 2019.

INDO-BANGLA PHARMACEUTICALS LTD

Notes to the Financial Statements

As at and for the year ended 30 June,2019

		Amount in Taka	
		30-Jun-19	30-Jun-18
3.00 Property, Plant and Equipment			
These have arrived at as under			
(A) At Cost			
Opening balance		686,464,201	557,442,914
Add: Addition during the year		126,821,731	129,021,287
Less: Disposal during the year		(11,770,992)	-
Total		801,514,939	686,464,201
(B) Accumulated Depreciation			
Opening balance		37,990,300	20,888,941
Add: Depreciation Charged for the year		21,974,546	17,101,359
Less: Adjusted during the year		(1,584,685)	-
Total		58,380,161	37,990,300
WDV as on 30.06.2019 (A-B)		743,134,778	648,473,901
Property, Plant & Equipment's details are shown in "Annexure-A"			
4.00 Capital Work in Progress			
These have arrived at as under			
A. Plant & Machinery			
Opening balance		-	-
Add: Addition during the year (Machinery)		67,266,943	94,597,147
Add: Addition Installation & other cost		-	1,245,850
Less: Transfer to Fixed Assets of Plant & Machinery		-	(95,842,997)
Closing Plant & Machinery		67,266,943	-
B. Land Development:			
Opening balance		5,545,920	-
Earth fill-up		2,575,680	5,545,920
Less: Transfer to Fixed Assets of land development		-	-
		8,121,600	5,545,920
Total (A+B)		75,388,543	5,545,920
5.00 Inventories			
This consists of the following			
Raw Material	Note : 17.01	89,645,280	78,512,350
Finished Goods	Note: 17.00	76,485,251	45,215,650
Work-in-Process	Note: 17.00	20,585,480	20,123,650
Spare Parts & Consumable Items	Note: 17.02.1	4,625,650	8,025,460
Packing Materials	Note: 17.03.1	11,525,450	14,875,680
		202,867,111	166,752,790

Inventories in hand have been valued at lower of cost or net realizable value as per IAS-2 and have been certified by management.

Amount in Taka	
30-Jun-19	30-Jun-18

6.00 Trade & Others Receivable

These have arrived at as under

A. Trade Receivable

Opening balance	188,215,610	163,732,470
Add: Sales during the year	740,714,183	659,971,100
Total	928,929,793	823,703,570
Less: Received during the year	750,125,650	635,487,960
Total trade receivables "Annexure-B"	178,804,143	188,215,610

B. Other Receivable (Interest on FDR)

	1,237,808	80,548
--	-----------	--------

Total (A+B)

	180,041,951	188,296,158
--	-------------	-------------

Ageing of Trade Receivable

More than six months	-	-
Less than six months	178,804,143	188,215,610
	178,804,143	188,215,610

The classification of receivables as required as Para 4, Schedule XI, Part-I of the Companies Act, 1994. are given below:

Receivable considered good in respect of which the company is fully secured.	-	-
Receivable considered good in respect of which the company holds no security other than the debtor personal security.	178,804,143	188,215,610
Receivables considered doubtful bad.	-	-
Receivable due by directors or others or other officers of the company or any of them either severally or jointly with any other person or debts due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
Receivables due by common under the same management.	-	-
The maximum amount of receivable due by any director or other officer of the company at any time during the year.	-	-
Total	178,804,143	188,215,610

7.00 Advance, Deposit and Prepayments

This consists of the following

Advance

Advance Income Tax	Note-7.01	88,094,202	62,799,447
Advance to Employees		2,156,450	2,513,250
Advance to Others	Note-7.02	133,483,210	53,906,350
		223,733,862	119,219,047

7.01 Advance Income Tax

Opening balance	62,799,447	41,950,748
Advance Tax paid during the year	24,301,531	20,603,700
Advance Tax paid during the year on Bank interest income	48,374	-
Advance Tax paid during the year on interest income from FDR	944,850	245,000
	88,094,202	62,799,447

		Amount in Taka	
		30-Jun-19	30-Jun-18
7.02 Advance to Others			
Goods and services		1,523,425	3,568,750
Tour		652,850	520,150
Office Rent		288,000	288,000
Land (Gazipur)		100,000,000	-
L/C Margin for Raw-materials		1,677,247	12,025,650
L/C Margin for Machinery		27,908,618	36,585,950
IPO Expenses		-	800,000
VAT current account		1,433,070	117,850
		133,483,210	53,906,350
8.00 Cash and Cash Equivalents			
These have arrived at as under:			
Cash in Hand		7,354,880	3,386,835
Cash at Bank	Note-8.01	53,226,547	58,292,784
Short Term FDR		100,000,000	30,000,000
		160,581,427	91,679,619
8.01 Cash at Bank			
Pubali Bank Ltd. Barishal Sadar Branch A/C 54490		100,444	761,013
Sonali Bank Ltd. Barishal Corporate Branch A/C. 3953		127,531	66,367
Islami Bank Bangladesh Ltd. Barishal Branch A/C no.10807		46,356,137	51,395,609
Islami Bank Bangladesh Ltd. Bhanga Branch A/C no.01405		192,028	188,944
Islami Bank Bangladesh Ltd. Bhanga Branch A/C no.01506		82,976	81,759
Islami Bank Bangladesh Ltd. Bhanga Branch A/C no.79513		34,312	747,029
One Bank Ltd. Barisal Branch A/C no.02579		4,146	5,296
Mercantile Bank Ltd. rampura Br. A/C: 56998		17,131	4,609,591
Mercantile Bank Ltd. Elephant road Br. A/C: 88298		2,611,111	-
Dutch-Bangla Bank Ltd. Barisal Branch A/C 1271100014683		1,221,187	437,177
City bank A/C no. 3102631598001		1,260,067	-
Standard Bank Ltd. Green Road Brance, A/C '05133000333		388,760	-
Eastern Bank Ltd Principal Branch A/C 1011360459420		830,718	-
		53,226,547	58,292,784

Cash balance was certified by the management. Bank balances were agreed with banks Statements certified by the respective banks.

9.00 Share Capital :

Authorized Capital

150,000,000 Ordinary Shares of Tk. 10 each.

Issued, Subscribed & Paid-up Capital:

102,300,000 Ordinary Shares of Tk. 10 each fully paid up.

1,500,000,000	1,500,000,000
1,023,000,000	730,000,000

		Amount in Taka	
		30-Jun-19	30-Jun-18
10.00 Retained Earnings			
	This amount consists of as follows		
	Opening balance	306,100,643	207,606,643
	Add :Net Profit for the year	155,226,689	98,493,999
	Less: IPO Expenses	(16,700,000)	-
	Less: Transfer to Share capital	(93,000,000)	-
		351,627,332	306,100,643
11.00 Deferred Tax Liability			
	This amount consists of as follows		
	Carrying Value of Property, Plant & Equipment (Annexure-A)	851,486,378	648,473,901
	As Tax Base	584,450,053	456,332,184
	Temporary Difference	267,036,325	192,141,717
	Deferred Tax Liabilities @25%	66,759,081	67,249,601
	Opening Deferred Tax Liability	67,249,601	38,180,191
	Deferred Tax Expenses	(490,520)	29,069,410
12.00 Provision for WPPF			
	Opening balance	7,576,461	6,797,898
	Add: Addition during the year	9,038,917	7,576,461
	Less: Transfer to WPPF Fund	(7,576,461)	(6,797,898)
	Total:	9,038,917	7,576,461
	Profit before Contribution to WPPF & Welfare Fund	189,817,263	159,105,691
	Provision for contribution @5% Profit After WPPF	9,038,917	7,576,461
13.00 Trade Payables			
	Opening balance	6,541,572	16,677,674
	Add: Purchase during the year	441,592,349	380,387,548
	Total	448,133,921	397,065,222
	Less: Adjustment during the year	442,025,650	390,523,650
	Closing balance (Details are in "Annexure -C")	6,108,271	6,541,572
14.00 Provision for Income Tax			
	Opening balance	97,573,822	73,608,002
	Add : Provision for the year (Note-21)	26,042,176	23,965,820
		123,615,998	97,573,822
15.00 Liabilities for Expenses			
	Telephone Bill	399.00	298.00
	Electricity Bill	198,928	152,805
	Directors Remuneration	150,000	150,000
	Salary & Wages	4,487,096	4,259,143
	Repairs and Maintenance	123,585	165,230
	Audit Fees with VAT	287,500	172,500
	Others	350,565	25,360
		5,598,073	4,925,336
16.00 Net Sales Revenue			
	Gross Sales	851,821,310	758,966,765
	Less: VAT @ 15%	111,107,127	98,995,665
	Net Sales (Net off VAT) (Details are in "Annexure-D")	740,714,183	659,971,100

		Amount in Taka	
		30-Jun-19	30-Jun-18
17.00	Cost of Sales:		
	This has been arrived as under;		
	Raw Material Consumed	337,300,529	268,872,485
	Add: Work in process (Opening)	20,123,650	19,565,430
	Less: Work in Process (Closing)	20,585,480	20,123,650
	Total Consumption	336,838,699	268,314,265
	Add: Manufacturing Overhead	58,435,912	53,919,676
	Add: Direct expenses	84,053,870	78,524,947
	Cost of Production	479,328,481	400,758,888
	Add: Finished Goods (Opening balance)	45,215,650	47,296,100
	Finished Goods Available	524,544,131	448,054,988
	Less: Finished Goods (Closing) (Details are in "Annexure-E")	76,485,251	45,215,650
	Less: Sample Costs	3,895,650	3,268,970
	Cost of Sales:	444,163,230	399,570,368
17.01	Raw Material Consumed		
	Opening balance	78,512,350	61,350,480
	Add: Material Purchased	348,433,459	286,034,355
	Import	310,243,449	219,211,365
	Local	38,190,010	66,822,990
	Less: Closing Raw Material	89,645,280	78,512,350
	Total	337,300,529	268,872,485
17.02	Manufacturing Overhead		
	Salary , Wages & allowance	7,607,936	6,283,900
	Cork & Cap	2,359,150	2,310,450
	Carton & Label	3,140,070	3,118,740
	Hand Glove, Tape, Gum Etc.	218,920	198,520
	Quality Control Expenses	750,970	761,535
	Accessories	2,669,180	2,675,415
	Apron & Uniform	599,230	578,465
	Carriage Inward	1,275,475	1,245,350
	Water bill	7,215	6,580
	Washing Expenses	3,375	2,820
	Maintenance of Machine & Consumable Items	17,748,260	17,721,363
	Electricity Bill Factory	1,991,775	1,731,276
	Maintenance of Factory Building	1,118,050	1,489,650
	Insurance expense	15,525	186,664
	Depreciation (Annexure-A)	18,930,781	15,608,948
		58,435,912	53,919,676
17.02.01	Maintenance of Machine & Consumable Items		
	Opening balance	8,025,460	8,256,980
	Purchase during the year	14,348,450	17,489,843
	Less: Closing balance	4,625,650	8,025,460
	Consumption	17,748,260	17,721,363
17.03	Direct expenses		
	Delivery Charges	746,890	641,250
	Packing Materials	82,160,670	76,575,486
	Medical Bag Expenses	420,680	405,325
	Cost of Literature	206,605	401,236
	Remission Settlement	519,025	501,650
	Total	84,053,870	78,524,947

		Amount in Taka	
		30-Jun-19	30-Jun-18
17.03.1 Packing Materials			
	Opening balance	14,875,680	14,587,816
	Purchase during the year	78,810,440	76,863,350
	Less: Packing Materials(Closing balance)	11,525,450	14,875,680
	Packing Materials Consumption	82,160,670	76,575,486
18.00 Administrative Expenses			
	Salary & allowance	12,536,746	11,247,672
	Director Remuneration	1,800,000	1,800,000
	Board Meeting Fee	525,000	385,000
	Travelling & Conveyance	2,900,620	2,510,235
	Entertainment	2,116,670	1,912,560
	Office Rent	662,400	591,100
	Printing & Stationery	1,959,155	2,012,564
	News Paper & Magazine	62,425	61,250
	Post & Telegram	445,905	441,285
	Insurance Premium	-	93,332
	License & Legal Fee	3,887,980	4,271,750
	Telephone & Mobile Bill	72,510	65,230
	Internet Bill	81,867	31,200
	Audit Fees	287,500	172,500
	Company secretarial, Regulatory Fee and AGM Expenses	2,112,931	-
	Electricity Bill	131,952	138,287
	Maintenance of Transport	1,844,905	1,636,250
	Securities service	757,160	672,540
	Bank Charge	359,115	99,365
	Others expenses	963,830	685,760
	Depreciation (Annexure-A)	3,043,765	1,492,411
	Total	36,552,436	30,320,291
19.00 Selling & Distributing Expenses			
	Salary & allowance	38,187,574	37,837,290
	Incentive Bonus	3,217,774	2,724,650
	TA & DA of Field Staff	3,659,725	3,157,565
	Carriage Outward	2,863,130	2,412,450
	Packing Materials-Selling & Distribution	3,531,510	3,512,485
	Sales Promotion	3,521,605	3,512,470
	Training & seminar Expenses	4,805,815	4,825,890
	Entertainment for Conference	2,714,575	2,212,535
	Gift & Presentation(Promotional Materials)	3,264,670	2,412,395
	Sample expense	3,895,650	3,268,970
	Travelling & Conveyance	12,054,615	11,025,630
	Total	81,716,643	76,902,330
20.00 Non Operating Income			
	Misc. Sales	4,827,050	3,521,690
	Interest on FDR	10,413,431	2,405,890
	Interest on Bank	481,216	-
	Profit/(Loss) on Sale of Fixed Assets	(4,186,308)	-
	Total	11,535,389	5,927,580

		Amount in Taka	
		30-Jun-19	30-Jun-18
21.00	Current Tax		
	Profit before tax as per account	180,778,346	151,529,230
	Add: Accounting depreciation	21,974,546	17,101,359
	Less: Tax base depreciation	103,198,343	100,156,816
	Less: Non Operating Income	11,535,389	-
	Current year Taxable profit	88,019,159	68,473,773
	Current Tax for Operating Income @ 25%	22,004,790	23,965,821
	Add: Tax on Non Operating Income @ 35%	4,037,386	-
	Total current Tax	26,042,176	23,965,821
22.00	Earnings Per Share (EPS)		
	This has been calculated in compliance with the requirements of IAS 33: Earnings Per Share, is the basic earning dividing by the weighted average number of ordinary shares outstanding at the end of the Period.		
	The composition of earnings per shares (EPS) is given below:		
	Net profit for the year	155,226,689	98,493,999
	Weighted Average number of ordinary shares outstanding	98,354,795	82,300,000
	Earnings Per Share (EPS)	1.58	1.20
	Weighted Average Number of Shares		
	73,000,000 Shares	73,000,000	73,000,000
	20,000,000 Shares	16,054,795	
	9,300,000 Shares	9,300,000	9,300,000
	102,300,000 Shares	-	-
	Weighted Average Number of Shares	98,354,795	82,300,000
23.00	Net Asset Value (NAV) Per Share		
	The composition of net assets value per share is given below:		
	Total Assets	1,585,747,672	1,219,967,435
	Less: Non-Current Liabilities+Current Liabilities	211,120,340	183,866,792
	Net Assets Value	1,374,627,333	1,036,100,643
	Number of ordinary shares outstanding	102,300,000	73,000,000
		13.44	14.19
24.00	Net Operating Cash Flows Per Share (NOCFPS)		
	Net Cash from Operating Activities	166,788,830	87,453,080
	Weighted Average Number of Shares	98,354,795	82,300,000
		1.70	1.06

Amounts in Taka	
30-Jun-19	30-Jun-18

25.00 Utilization of IPO Fund

Utilization position of IPO proceeds up to 30 June 2019 was as under;

SL. No.	Purpose as per prospectus	Amount as per Prospectus	Utilized during the year	Total Utilization
	Construction and other civil works	58,580,000	-	-
	Machineries	124,720,000	89,463,090	89,463,090
	IPO expenses	16,700,000	16,700,000	16,700,000
		200,000,000	106,163,090	106,163,090

The company raised Tk. 200,000,000 divided into 20,000,000 ordinary shares of Tk. 10 each through IPO on September 13, 2018. The company utilized Tk. 106,163,090 in total up to June 30, 2019 for the purposes described above as certified by independent auditor, G. Kibria & Co, Chartered Accountants.

26.00 Cash receipts from customers

Opening receivable	188,215,610	163,732,470
Add: Sales during the year	740,714,183	659,971,100
Less: Closing receivable	(178,804,143)	(188,215,610)
	750,125,650	635,487,960

27.00 Cash receipts from others income

Misc. Sales	4,827,050	3,521,690
Bank Interest	9,737,387	2,450,000
	14,564,437	5,971,690

28.00 Cash payment to suppliers

Purchase (RM,spare,packing)	441,592,349	380,387,548
Opening Accounts Payable	6,541,572	16,677,674
Closing Accounts Payable	(6,108,271)	(6,541,572)
Opening Advance goods	(15,594,400)	(4,256,320)
Closing Advance goods	3,200,672	15,594,400
	429,631,922	401,861,730

29.00 Acquisition of property, plant and equipment

Property, Plant & Equipment addition during the year	126,821,731	129,021,287
Less: Adjustment:	42,585,950	58,567,465
Closing Advance L/C Margin for Machinery	36,585,950	58,567,465
Sale of Machinery	6,000,000	-
	84,235,781	70,453,822

30.00 Paid for Work In Progress

	69,842,623	5,545,920
--	-------------------	------------------

31.00 Advance paid for L/C Margin Machinery

	27,908,618	36,585,950
--	-------------------	-------------------

Amounts in Taka	
30-Jun-19	30-Jun-18

32.00 Reconciliation of Net Profit with cash flows from Operating Activities:

Profit before Tax	180,778,346	151,529,230
Add: Depreciation on property, plant and equipment	21,974,546	17,101,359
	202,752,892	168,630,589
Add: Increase in Trade & Other Receivables	8,254,207	(24,439,030)
Less: Increase in Inventories	(36,114,321)	(15,695,984)
Less: Decrease in Trade Payables	(433,301)	(10,136,102)
Add: Increase in Liabilities for Expenses	672,736	125,814
Add: Increase in Liability for contribution to W.P.P.F	1,462,456	778,564
Add: Increase in Advance, Deposit & Prepayments	11,302,608	(10,962,071)
Add: Capital Loss for Sale of Machinery	4,186,308	-
Less: Income Tax Paid	(25,294,755)	(20,848,700)
	166,788,830	87,453,080

33.00 Related parties Transactions:

The company carried out a number of transactions with related parties. The following are the related parties transactions of the Indo-Bangla Pharmaceuticals Ltd has been disclosed as required by BAS 24 Related Party Disclosures.

(a) Remuneration

Name	Designation	Nature of Transaction	Amount in (BDT)	
			2018-2019	2017-2018
Mr. A.F.M Anowarul Huq	Managing Director	Remuneration	1800000	1,800,000

(b) Board meeting fee

Name	Designation	Nature of Transaction	Amount in (BDT)	
			2018-2019	2017-2018
Mrs. Aziza Yeasmin	Chairman	Board Meeting fee	50,000	50,000
Mr. A.F.M Anowarul Huq	Managing Director		55,000	50,000
Mrs. Hafiza Yeasmin	Director		20,000	50,000
Md. Amin-Ur-Rashid	Director		50,000	40,000
Sayedda Huq	Director		50,000	40,000
Fatima Parvin	Director		55,000	35,000
Mst. Shanaj Akter	Director		40,000	35,000
Mizanur Rahman	Director		50,000	35,000
Md. Golam Rabbani	Director (Represented of ICB)		20,000	-
S.M. Harun Or Rashid	Independent Director		50,000	20,000
Md. Monirujjaman	Independent Director		45,000	15,000
Md. Firoz Khan	Independent Director		40,000	15,000

34.00 Production Capacity and Utilization

Item	Unit	Production Capacity		Actual Production		Capacity Utilization	
		2019	2018	2019	2018	2019	2018
Tablet	Million Pcs	2700	1500	2250	1208	83%	81%
Capsule	Million Pcs	535	435	450	281	84%	65%
Liquid/Phs	Million ML	350	350	330	320	94%	91%

35.00 The requirements of schedule XI, Part II, note-5 Para 3, of the company Act.1994.

Employees	2019	2018
Number of employees whose salary was below Tk. 3,000.00	-	-
Number of employees whose salary was above Tk. 3,000.00	224	219

36.00 Cost of goods sold from import as per Para 8, Schedule XI, Part-II of the Companies Act 1994 is required:

During the period 1st July 2018 to 30th June 2019 total Value of import in respect of raw materials stands equivalent USD 3,928,079 on CIF basis. Details are as follows:

Particulars	Amount In BDT	
	2019	2018
Import of raw Materials	310,243,449	219,211,365
Import of Packing Materials	15,787,180	13,125,865
Total:	326,030,629	232,337,230

37.00 Events after the Reporting Period

a) The company acquired and registered 145.43 decimal land on 14 October 2019 at 1st phase out of 1028 decimal land for which bayna deed was made earlier. The land is located at Mothajuri, Fulbaria, Kaliakoir, Gazipur.

b) The Board of Directors at its board meeting held on 28 October 2019 recommended Cash 2% for all Shareholders excluding the Sponsors & Directors (excluding ICB) and Bonus-9% for all shareholder of the paid up Capital for the year ended 30 June 2019. This dividend is subject to final approval by the shareholders at the forthcoming annual General Meeting (AGM) of the company.

38.00 Financial Risk Management

The management of company has overall for the establishment and oversight of the company's risk management framework. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. The company has exposure to the following risk for its use of financial instruments.

Credit Risk

Liquidity Risk

Market Risk

Credit Risk

Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the company's receivables. Management has a credit policy in place and exposure to credit risk monitored on an ongoing basis. As at 30th June 2019 substantial part of the receivables are those from its related company and subject to insignificant credit risk. Risk exposures from other financial assets. i.e. Cash at bank and other external receivables are nominal.

Liquidity Risk

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (cash and cash equivalents) is to ensure as far as possible, that it will always have sufficient liquidity to meet its liabilities when due under both normal and stressed conditions without incurring unacceptable losses or risking damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalent to meet expected operational expenses including financial obligation through preparation of the cash flow forecast with due consideration of time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date. In extreme stressed conditions the company may get support from the related company in the form of short term financing.

Market Risk

Market risk is the risk that any changes in market prices such as foreign exchange rates and interest will affect the company's income or the value of its holdings financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

(a) Currency risk

The company is exposed to currency risk on certain revenues and purchases such as revenue from foreign customers and import of raw materials, machineries and equipment. Majority of the company's foreign currency transactions are denominated in USD and relate to procurement of raw materials, machineries and equipment from abroad.

(b) Interest rate risk

Interest rate risk is the risk that arises due to changes in interest rates on borrowing. The foreign currency loan is subject to floating rates of interest. Local loans are, however, not significantly affected by fluctuations in interest rate risk. The company has not entered into any type of derivative instrument in order to hedge interest rate risk as at the reporting date.

INDO-BANGLA PHARMACEUTICALS LTD
Schedule of Property Plant & Equipment
As at 30 June 2019

Particulars	COST					Rate	DEPRECIATION				Written Down Value as on 30.06.2019
	Balance as on 01.07.2018	Addition during the year	Disposal during the year	Total Cost as at 30.06.2019	Total as at 30.06.2019		Adjusted during the year	Charge during the year	Balance as on 01.07.2018	Total as at 30.06.2019	
Land & Land Development	45,487,485	-	-	45,487,485	-	0%	-	-	-	-	45,487,485
Building	154,040,627	36,725,945	-	190,766,572	-	2.5%	-	7,956,266	3,874,771	11,831,038	178,935,534
Machineries & Equipment	433,215,086	75,307,366	11,770,992	496,751,459	11,770,992	3%	1,584,685	24,422,221	13,664,726	36,502,262	460,249,198
Micro biological Lab	8,652,165	2,896,570	-	11,548,735	-	3%	-	21,630	309,606	331,236	11,217,499
Factory Air Condition	6,525,480	-	-	6,525,480	-	10%	-	108,758	641,672	750,430	5,775,050
Generator	4,352,879	-	-	4,352,879	-	3%	-	381,916	119,129	501,045	3,851,834
Furniture & Fixture	7,774,694	2,125,500	-	9,900,194	-	10%	-	1,812,564	720,200	2,532,765	7,367,429
Office Equipment	4,962,146	-	-	4,962,146	-	10%	-	1,013,424	394,872	1,408,296	3,553,850
SEP Decoration	12,054,850	-	-	12,054,850	-	10%	-	200,914	1,185,394	1,386,308	10,668,542
Office Decoration	2,106,500	-	-	2,106,500	-	10%	-	62,629	204,387	267,016	1,839,484
Computer	399,490	240,500	-	639,990	-	10%	-	50,788	48,899	99,688	540,302
Air Condition	354,170	-	-	354,170	-	10%	-	40,942	31,323	72,265	281,905
Transport	2,080,294	9,525,850	-	11,606,144	-	10%	-	668,683	458,689	1,127,372	10,478,772
Water Plant	2,512,960	-	-	2,512,960	-	10%	-	726,811	178,615	905,426	1,607,534
EIP Plant	1,945,375	-	-	1,945,375	-	10%	-	522,753	142,262	665,015	1,280,360
Balance as on 30 June,2019	686,464,201	126,821,731	11,770,992	801,514,939	11,770,992		1,584,685	37,990,300	21,974,546	58,380,161	743,134,778
Balance as on 30 June,2018	557,442,914	129,021,287	-	686,464,201	-		-	20,888,941	17,101,359	37,990,300	648,473,901

Allocation of Depreciation

Factory	18,930,781
Administration	3,043,765
	<u>21,974,546</u>

INDO-BANGLA PHARMACEUTICALS LTD.

Trade Receivables

As at 30th June, 2019

Annexure-B

SI No	Name of Party	Address	Amounts in Taka	
			30-Jun-19	30-Jun-18
1	Barendra distribution	181/A,Upo shohor, Newmarket, Rajshahi.	6,025,465	9,542,150
2	Saimun drug, Khulna	17/3, Durgabari Road, Maymansing.	5,568,450	8,265,980
3	Shafi Medical Hall	25, BCDS Market, Maik Potti, Jessore	5,145,685	7,548,630
4	Mannan Pharmacy	BRTC Bus Station, 87,Shamoli Para, Ulla Para	5,521,350	7,145,650
5	Shaha pharmacy	Ranjit Shaha, Taramoni Medical Hall, 12,College Mor, Sherpur	6,025,480	5,590,250
6	Rakib medical hall	Rakibul Hasan,65, Hatirkumrul, Oil Pump, Sirajgong	6,523,470	5,124,630
7	khokon medical hall	75,Sarder Super Market, Satkhira, Khulna	5,542,650	6,587,450
8	Rafiq medical hall	85,Kadamtala Bazer, Nator.	2,521,860	5,296,320
9	Deep medical hall	60,Hisan Medicine Market, Rangpur.	5,241,850	7,242,150
10	Iqbal medical hall	27,Sadar Road, Kishoregong.	4,523,650	5,236,580
11	City pharmacy	Bishnu podo Shaha,12, Thana More Golachipa.	6,584,700	6,020,130
12	Badal pharmacy	Sumit Sikder,67, Natun Bazar, Gopalgonj.	3,568,950	4,236,920
13	Kanai Lal Pharma	Kanai Lal Das,102, Laheri Para, Faridpur.	65,210	5,012,625
14	Rumman Medical	110,Nodi Bangla Market, 2 nd floor, Shatmata, Bogura.	3,541,250	3,125,980
15	Ali Medical	Soroware Hossain, 115,Sadar Road, Kishoregonj.	2,565,820	3,012,950
16	Shahin Medical Hall	76,Nurpur Market, Babubazar, Dhaka	3,256,250	2,436,520
17	Sundorban Pharmacy	Tofazzel Hossen, 24,Station Road, Comilla.	4,875,620	4,625,140
18	Jannat Medical	Kaysar Ahmed, 45,Station Road, Natore.	3,265,410	2,714,685
19	Bangladesh Medical Hall	17,Durgabari Road, Moymonsing.	2,568,945	2,235,960
20	City Medical Hall	33,Datta Building, Infort of Town Hall, Magura.	3,925,420	3,569,870
21	Tanvir Medical Hall	Golam Soroware Hossain, 21,Station Road, Hatia.	3,562,895	3,325,140
22	Asha Drug	Mr. Azad, 42/A Heraj Market, Khulna.	2,254,165	2,436,985
23	Shams pharmacy	167, Bijoy Bitan, Hali Shohor, Hazari Lane, Chittagong.	3,521,450	3,245,620
24	Aroga Niketon	Monorangon Pal,12,Sadar Road,Dohar,Dhaka.	1,754,875	2,012,450
25	Basin Medical Hall	M.A Mannan, 55,Madhappur,Narshingdi.	3,526,980	3,456,985
26	Lovely Enterprise, Feni	Mr. Bimal, 34,Station Road,Feni.	1,625,420	1,535,970
27	Janata Medical Hall	15,Hazi Super Market, Rangpur.	3,526,985	3,925,460
28	Rup Saj Corner	Mr. Arif, 27, Bazar Road, Sayedpur.	5,241,350	5,021,430
29	Helal Drug	Md. Issa,55, Laxmipur Mor, Rajshahi.	3,512,475	3,487,560
30	Utsab Meidcal	Deb Dulal Shaha, 15, Sadar Road, Kishoregong.	4,012,650	3,923,341
31	Taramoni Medical Hall	Biplob Das, 7,Khoda Box Road, Faridpur.	5,874,230	5,632,980
32	Prodip Medical Store	Md. Rakibul Islam, 18, M.K Road, Jessore.	5,214,780	6,524,780
33	Tanzila Medical Hall	19, Merina Nodi Bangla Market, Bogura.C25	4,523,150	5,578,960
34	Badhan Pharmacy	28,Bangabandhu Sarak, Jhinaidah.	2,135,620	4,215,630
35	Lia Arogo Niketon	G.C Market, 170 Hazari Lane, Chittagong.	2,251,480	4,789,250
36	Kanai Lal Medical Hall	Rajon Lal Das, 11Bhanga Bazar,Bhanga Faridpur.	1,520,150	3,230,170
37	Shah Medical hall	320,Chandina bazar,Comilla	523,625	650,200
38	Dottho Farma	120,Fai bazar, Chandina, Comilla	1,052,865	325,800
39	Johir Farma	Rammohon bazar,25 Pan potti, Borora,Comilla	1,256,850	660,100
40	Shades Pharma	135,Chatkhil,Noakhali	215,420	341,580
41	Sheto Medical hall	75,Jatrabari, Dhaka.	25,450	520,140
42	Bayewan Medical hall	118,Shonir Akhra, Jatrabari, Dhaka	250,320	525,800
43	Alia Pharma	54, Aziz supermarket,Khulna	2,325,120	225,630
44	Nazmul Pharma	120,Laksam bazar, Comilla	250,150	480,450
45	Mayer Doa Medical hall	135, Kadamtala Bazer, Nator	165,230	152,400
46	Asif pharma	120, Durgabari Road, Moymonsing.	120,420	135,450
47	Priya Medical hall	25, Nurpur Market, Babubazar, Dhaka	375,450	220,480
48	Alif Medical hall	120, Merina Nodi Bangla Market, Bogura.	1,150,250	185,200
49	Billal Pharma	Alikamura Bazar, Chandina, Comilla	425,630	295,780
50	Rayhan Medical hall	Batagashi Bazar, Chandina, Comilla	250,480	102,685
51	Monjur Pharma	129 Akborsha, Khalshe, Chittagong	2,245,168	145,300
52	Shapla Medical hall	Konapara, Paradogar,Jatrabari,Dhaka	1,020,099	295,850
53	Tabassume Medical hall	Rarikandi,Matlab,Chandpur	2,215,460	136,950
54	Onanna Pharma	Changarchor, Matlab, Chandpur	611,241	250,360
55	New Opposom Pharmacy	Durga bari Road, Moymonshing	-	2,956,225
56	Ishan Medical hall	Market holl, Rongpur	-	2,556,225
57	Sha Medical hall	College road, Sherpur	-	3,544,588
58	Sagor Pharmacy	Shehikh hat, Shylet	-	3,597,570
59	Ma Moni Medical Hall	Bazar road, Cox bazar	-	2,997,566
60	Jonokollan Distribution	Mosco Road, Suprim Jut Meal Gate, Sreepur, Baipail, Asholia, Dhaka.	2,025,480	-
61	Sattar Distribution	Haji Abdul Ali Super Market, 2nd Floor, Babubazar, Dhaka.	2,025,450	-

62	S.T.Barakas	Sector 12,Road no.14. Uttara, dhaka	5,536,965	-
63	Mizan Distribution	Barisal Sadar, Barisal	6,125,630	-
64	Shahid Distribution	Nathollabad station road, Barisal Sadar, Barisal	7,695,250	-
Total:			178,804,143	188,215,610

INDO-BANGLA PHARMACEUTICALS LTD.

Trade Paybles

As at 30th June, 2019

Annexure-C

Sl. No	Name of the Medical Hall	Address	Amounts in Taka	
			30-Jun-19	30-Jun-18
1	Pirojpur Printing & Packing	185, Fakirapul, Motijhil, Dhaka.	850,250	484,677
2	S.T.S Foil Corporation	Fakirapul, Motijhil, Dhaka.	1,214,560	1,119,748
3	M.K.Printers	103, Arambag, Motijhil, Dhaka.	565,850	492,997
4	Jass Corporation	Asulia, Savar.	1,350,250	1,667,639
5	Oni Printers	240/3, Fakirapul Motijhil, Dhaka.	523,560	1,399,872
6	Nahid Perfumary & Chemical	47/C, Midford, Dhaka.	336,980	214,510
7	Riya Perfumary	Midford, Dhaka.	125,470	177,353
8	Brothers Hood Chemical	Agrabad, Chittagong.	121,585	206,171
9	Desh Foil Limited	Sabujbag, Dhaka.	254,750	155,368
10	Banik Stors	Bazar Road, Barisal.	98,316	167,026
11	Padma Cap	Opsonin Mor, Barisal.	215,470	139,189
12	Global Capsul	Rupatoli, Barisal.	154,820	317,022
13	Rouf Medical Hall	Babu Bazar, Dhaka	250,630	-
14	Rabby Cartoon	Barisal	45,780	-
Total Taka			6,108,271	6,541,572

INDO-BANGLA PHARMACEUTICALS LIMITED

**Net Sales Statement
As at 30th June, 2019**


Annexure-D

Sl. No	Name of the Product	Quantity (Box)	Amount in Tk (2019)	Quantity (Box)	Amount in Tk (2018)
1	Tab. Dextrin	625,450	18,138,050	519,518	18,183,147
2	Indomoxin PFS	1,250,120	25,002,400	1,201,282	24,025,636
3	Tab. Indofenac	1,365,250	24,574,500	1,286,797	21,875,552
4	Tab. Indostin-R	865,239	49,318,623	734,003	33,030,113
5	Tab. Indocal-D	763,241	9,922,133	634,147	12,682,944
6	Tab. Indoizith	2,014,635	104,761,020	-	-
7	Tab. I-Cet	752,410	12,790,970	2,153,616	36,611,464
8	Tab. I-Pedom	169,470	3,643,605	675,546	13,510,916
9	Cap. Protobit 20	1,369,068	112,263,576	933,328	73,732,906
10	Tab. Cipro-I	568,750	22,181,250	76,781	3,071,234
11	I-B Oral Saline	521,437	23,464,665	566,054	25,472,420
12	Tab. Indoprox Mix	568,920	54,047,400	410,161	40,195,809
13	Tab. Metrol 400mg	425,150	22,532,950	401,754	19,685,958
14	Cap. Indotetra-250mg	76,510	3,978,518	584,161	30,376,354
15	Tab. Inket	698,033	16,054,759	712,600	15,677,191
16	Tab. Relise	386,570	17,009,080	976,455	29,293,644
17	Tab. Riboflavine	-	-	471,206	24,973,900
18	Zins Syrup	-	-	348,290	4,876,057
19	Syrup Indoplex 100/200	-	-	334,062	6,681,243
20	Seplon 60 & 100	1,125,487	18,007,792	482,015	7,712,243
21	Indoflox PFS	1,083,975	32,519,250	1,119,030	33,570,911
22	Tab. Indocal	1,025,682	10,256,820	711,992	7,119,917
23	Tab. Paramol Plus	365,980	26,716,540	914,836	48,486,298
24	Tab. Trialugel	-	-	263,063	15,783,799
25	Fixim PFS	542,684	35,274,460	21,563	1,401,624
26	Cap. Indofenac TR	254,780	16,815,480	1,391,704	77,935,402
27	Tab. Neostin-R New	587,127	47,557,287	175,729	14,409,753
28	Tab. Indocal (L)	165,543	36,419	2,175,768	478,669
29	Tasty Salt Saline	184,750	9,791,750	128,685	7,077,679
30	Tab. P	125,470	4,140,510	133,362	4,400,933
31	N-X	50,402	2,016,080	16,480	708,651
32	Indozith 15 PFS	-	-	81,727	2,124,905
33	Indozith 30 PFS	-	-	56,205	2,810,256
34	Tab. Makmaul Sanagra-	250,685	2,256,165	37,615	1,993,572
35	Cap. I - CIN	82,565	3,632,860	-	-
36	Tab. Calfresh-M	52,635	947,430	-	-
37	Tab. Makmaul Sanagra-	43,252	7,352,840	-	-
38	Cap. Indomoxin 250	185,450	3,709,000	-	-
	Total Taka		740,714,183	-	659,971,100

INDO-BANGLA PHARMACEUTICALS LIMITED
FINISHED GOODS
As at 30th June, 2019

Annexure-E

Sl. No	Name of the Product	Quantity (Box)	Taka (30/06/2019)	Quantity (Box)	Taka (30/06/2018)
1	Tab. Dextrin	5,820	168,780	8,402	294,452
2	Indomoxin PFS	8,540	170,800	9,014	180,686
3	Tab. Indofenac	18,950	341,100	14,309	201,030
4	Tab. Indostin-R	32,564	1,856,148	36,472	1,641,234
5	Tab. Indocal-D	92,540	1,203,020	80,003	800,182
6	Tab. Indoziith	-	-	65,287	1,309,737
7	Tab. I-Cet	121,450	2,064,650	196,141	3,339,504
8	Tab. I-Pedom	25,410	546,315	148,020	2,964,403
9	Cap. Protobit 20	18,317	1,501,994	24,178	1,925,887
10	Tab. Cipro-I	45,835	1,787,565	37,582	1,133,448
11	I-B Oral Saline	52,360	2,356,200	56,405	2,538,212
12	Tab. Indoprox Mix	25,415	2,414,425	94,072	9,219,017
13	Tab. Metrol 400mg	20,150	1,067,950	31,147	1,650,785
14	Cap. Indotetra-250mg	87,540	4,552,077	76,510	3,988,941
15	Tab. Inket	45,320	1,042,360	92,542	2,035,924
16	Tab. Relise	45,210	1,989,240	299,519	8,985,559
17	Tab. Riboflavine	-	-	-	-
18	Zins Syrup	-	-	-	-
19	Syrup Indoplex 100/200	-	-	-	-
20	Seplon 60 & 100	26,350	421,600	-	-
21	Indoflox PFS	15,890	476,700	-	-
22	Tab. Indocal	14,565	145,650	-	-
23	Tab. Paramol Plus	32,590	2,379,070	-	-
24	Tab. Trialugel	-	-	-	-
25	Fixim PFS	12,450	809,250	-	-
26	Cap. Indofenac TR	15,680	1,034,880	-	-
27	Tab. Neostin-R New	25,960	2,102,760	-	-
28	Tab. Indocal (L)	32,462	7,142	-	-
29	Tasty Salt Saline	12,450	659,850	15,005	830,775
30	Tab. P	15,685	517,605	-	-
31	N-X	-	-	50,402	2,175,874
32	Indozith 15 PFS	25,630	666,380	-	-
33	Indozith 30 PFS	32,650	1,632,500	-	-
34	Tab. Makmaul Sanagra-100	125,450	1,129,050	-	-
35	Cap. I - CIN	250,120	11,005,280	-	-
36	Tab. Calfresh-M	32,320	581,760	-	-
37	Tab. Makmaul Sanagra-100	42,550	7,233,500	-	-
38	Cap. Indomoxin 250	25,673	513,460	-	-
39	Cap. Indomoxin 500	113,053	20,349,540	-	-
40	Tab. Metrol 200 mg	35,850	1,756,650	-	-
Total Taka			76,485,251		45,215,650



Corporate Office: Plot#183 (7th Floor) Block#B
Road#4, Ahmed Akbar Sobhan Road, Basundhara R/A,
Baridhara, Dhaka-1229. Phone- 09678777995.
E-mail : info@indo-banglapharma.com
Web : www.indo-banglapharma.com
Factory : College Road, Barisal, Phone: 0431-61028, 0431-2174977.

